[ { "id": 657, "name": "Bikanta", "slug": "bikanta", "former_names": [], "small_logo_thumb_url": "/company/thumb/missing.png", "website": "http://bikanta.com", "all_locations": "San Francisco, CA, USA; Berkeley, CA, USA", "long_description": "Bikanta is introducing revolutionary nanodiamond-based technology to push the boundaries of current medical imaging and diagnostics, allowing researchers to answer questions and medics to detect diseases that they currently cannot.\r\n\r\nA nanodiamond is forever. They are brightly fluorescent, infinitely stable, non-toxic, functionalizable and can be used for background-free optical imaging. Early results have improved the signal by as much as 100-fold over conventional fluorescence imaging techniques. Bikanta’s vision is to redefine the boundaries of medical diagnostics by delivering cutting-edge imaging probes and background-free optical imaging.", "one_liner": "Nano-diamonds for cancer detection", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1398907618, "tags": [ "Nanomedicine" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2014", "status": "Inactive", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/bikanta", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2014/bikanta.json", "year_founded": 2013, "city": "San Francisco", "country": "US", "linkedin_url": "", "x_url": "", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/bikanta", "github_url": null, "logo_url": null, "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 39317, "full_name": "Ambika Bumb", "title": "Founder/CEO", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/ambikabumb", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/ccaba4cc0a318e9cab9dc96716bacb121547116f.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 739, "name": "Notable Labs", "slug": "notable-labs", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/c2bf47d120c3bdde2a9ad11d9f05f1c08a72ca0e.png", "website": "http://notablelabs.com", "all_locations": "San Francisco, CA, USA; Foster City, CA, USA", "long_description": "Notable Labs is building a personalized drug discovery platform to identify treatment options for relapsed and refractory cancer patients — starting with blood cancer — to address the long tail of cancer treatment. We look at a person’s actual cancer cells, test combinations of FDA approved drugs, and see which combinations kill the cancer cells and leave the healthy cells alive. We focus on combinations because cancer is often difficult to target with just one drug and starting with a single drug can lead to resistant clones or relapse. We're building a highly automated lab in Foster City running on our custom software and are currently testing relapsed/refractory cancer patients as well as samples from a variety of pharma/biotech partnerships.\r\n\r\nhttps://www.notablelabs.com/careers", "one_liner": "Personalized drug discovery for blood cancer.", "team_size": 40, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1407578442, "tags": [ "Biotech", "Drug discovery", "Oncology" ], "tags_highlighted": [], "top_company": true, "isHiring": true, "nonprofit": false, "batch": "Winter 2015", "status": "Public", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": true, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/notable-labs", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2015/notable-labs.json", "year_founded": 2014, "city": "San Francisco", "country": "US", "linkedin_url": "", "x_url": "https://twitter.com/notablelabs", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/notable-labs-2", "github_url": "https://github.com/NotableLabs", "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/c2bf47d120c3bdde2a9ad11d9f05f1c08a72ca0e.png", "app_video_url": null, "dday_video_url": "https://bookface-images.s3.us-west-2.amazonaws.com/video_event/10/1427240098052-kikiobbw3fcx47vi-0fb11434a5aa7dfed43fbe66e4b7cb1c/657f6ab39a6ef44174d31a96ba482867.mp4?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIAQC4NIECABPQ2AHNW%2F20261020%2Fus-west-2%2Fs3%2Faws4_request&X-Amz-Date=20261020T022629Z&X-Amz-Expires=3600&X-Amz-SignedHeaders=host&X-Amz-Signature=1ec308578ecc7d87fd1dac00354b1e5c47a8c16627905c134810ce30ed926a49", "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 69577, "full_name": "Matthew De Silva", "title": "Founder/CEO", "founder_bio": "", "is_active": false, "linkedin_url": "https://www.linkedin.com/in/matthewdesilva/", "x_url": "https://twitter.com/MDe_Silva", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/9f6eebea28438330b0e1b0a312affcdf60fa89eb.jpg" }, { "user_id": 69576, "full_name": "Pete Quinzio", "title": "Founder", "founder_bio": "", "is_active": false, "linkedin_url": "https://www.linkedin.com/in/peter-quinzio-26083a35", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/e95bef4a9fd59491bdf3fab81ee4a4fc89118bcf.jpg" } ], "jobs": [ { "id": 16239, "title": "Senior Software Engineer - Full Stack", "url": "https://www.ycombinator.com/companies/notable-labs/jobs/Ey5oHo8pO-senior-software-engineer-full-stack", "location": "Foster city, CA", "type": "Full-time", "role": "Engineering", "role_type": "Full stack", "salary_range": "", "equity_range": "", "experience": "3+ years", "visa": "US citizen/visa only", "skills": [ "Amazon Web Services (AWS)", "Django", "Git", "GraphQL", "JavaScript", "Python", "React", "Docker" ] }, { "id": 37703, "title": "Product Development Scientist / Senior Assay Development Scientist", "url": "https://www.ycombinator.com/companies/notable-labs/jobs/ti2HBnyyd-product-development-scientist-senior-assay-development-scientist", "location": "Foster City, CA", "type": "Full-time", "role": "Science", "role_type": "Laboratory", "salary_range": "", "equity_range": "", "experience": "6+ years", "visa": "US citizen/visa only", "skills": [] }, { "id": 37704, "title": "Principal Product Development Scientist", "url": "https://www.ycombinator.com/companies/notable-labs/jobs/kF9VM8qjw-principal-product-development-scientist", "location": "Foster City, CA", "type": "Full-time", "role": "Science", "role_type": "Laboratory", "salary_range": "", "equity_range": "", "experience": "11+ years", "visa": "US citizen/visa only", "skills": [] } ], "news": [ { "title": "Personalized cancer treatment startup Notable Labs nabs $40M Series B - MedCity News", "url": "https://medcitynews.com/2019/07/personalized-cancer-treatment-startup-notable-labs-nabs-40-million-series-b/", "date": "Jul 16, 2019" }, { "title": "Notable raises $40 million to personalize cancer drug regimens | VentureBeat", "url": "https://venturebeat.com/business/notable-raises-50-million-to-personalize-cancer-drug-regimens/", "date": "Jul 16, 2019" } ], "launches": [] }, { "id": 805, "name": "Lucira Health", "slug": "lucira-health", "former_names": [ "Diassess" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/c16f624e7c7aac96877a792583de496fc66b4a02.png", "website": "https://www.lucirahealth.com/", "all_locations": "Emeryville, CA, USA", "long_description": "Diassess Inc. is revolutionizing the way infectious diseases are prevented, diagnosed, and monitored by developing the tools necessary to empower people to become knowledgeable about their health. We produce inexpensive, disposable health diagnostic hardware that transforms any smartphone into a portable, real-time health-monitoring device for rapid, accessible, multiplexed analysis of bodily fluids anywhere in the world.", "one_liner": "Next generation infectious disease test kits", "team_size": 43, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1416306600, "tags": [ "Health Tech", "Diagnostics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2015", "status": "Public", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/lucira-health", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2015/lucira-health.json", "year_founded": null, "city": "Emeryville", "country": "US", "linkedin_url": "https://www.linkedin.com/company/lucira-health/", "x_url": "", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/diassess", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/c16f624e7c7aac96877a792583de496fc66b4a02.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 62847, "full_name": "Debkishore Mitra", "title": "Founder", "founder_bio": null, "is_active": true, "linkedin_url": "http://www.linkedin.com/in/debkishoremitra", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/f7dd5d25bfd086d4fdf1d75520f770bc6636402c.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 840, "name": "X-Zell", "slug": "x-zell", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/3fafbc0fbed91c91e5664f3b665740b3a037febe.png", "website": "http://www.x-zell.com", "all_locations": "Bangkok, Thailand; Düsseldorf, NRW, Germany", "long_description": "X-ZELL™ is a global start-up specialising in rare cell detection technology. \r\n\r\nBacked by Y Combinator and various high-profile angel investors from around the globe – among them Gmail creator Paul Buchheit – X-ZELL™ has developed a world-first platform technology capable of isolating and visualizing rare and abnormal cells such as Circulating Endothelial Cells (CEC).\r\n\r\nX-ZELL™’s platform technology is based on four core modules covering the entire spectrum from blood processing through to cell analysis and reporting – with every step performed in-house using patented and proprietary technology.\r\n\r\nBy combining the wisdom of 4,000 years of pathologic research with X-ZELL™’s own, cutting-edge technology, \r\nX-ZELL™ ensures robust results and maximum clinical utility across a broad range of medical applications – from research through to medication management, companions diagnostics, relapse control and diagnostic decision-making.\r\n\r\nMore information on www.x-zell.com and @XZELLInc", "one_liner": "Early, pain-free cancer detection. ", "team_size": 19, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1416312163, "tags": [ "Medical Devices" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2015", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "Thailand", "Germany", "Southeast Asia", "Europe", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/x-zell", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2015/x-zell.json", "year_founded": 2014, "city": null, "country": "TH", "linkedin_url": "https://www.linkedin.com/company/xzell", "x_url": "https://twitter.com/XZELLInc", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/x-zell", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/3fafbc0fbed91c91e5664f3b665740b3a037febe.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 8648, "full_name": "Sebastian Punyaratabandhu Bhakdi", "title": "Founder", "founder_bio": "Sebastian started out as a physician at the University Hospital of Freiburg, Germany and earned a Degree in International Health at the Autonomous University of Barcelona, Spain, which made him realize that health services have to be accessible for all. A Research Fellowship from the German Research Foundation helped him to create his first patent which he used to found X-ZELL. He remains its CEO and Principal Investigator, growing the company to solve the world's cancer screening challenge.", "is_active": true, "linkedin_url": "https://www.linkedin.com/pub/sebastian-chakrit-punyaratabandhu-bhakdi/4a/357/8a3", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/21502453739200d02d1cc4addb93587a8578017b.jpg" }, { "user_id": 9916, "full_name": "Prapat Suriyaphol", "title": "Founder", "founder_bio": null, "is_active": true, "linkedin_url": "http://th.linkedin.com/pub/prapat-suriyaphol/17/5b0/3b2", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/e76c0210b5ecdef4337b186bee4ae8bf0d2642aa.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 955, "name": "Klarismo", "slug": "klarismo", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/9b735035a5d3492fb1057eb5b35bd5b80ee018df.png", "website": "http://klarismo.com", "all_locations": "San Francisco, CA, USA", "long_description": "Fully-automated Quantitative MR Image Analysis.\r\n\r\nOur software converts a user’s full body magnetic resonance scan (MRI) into a 3D virtual model of their body in the cloud. The model is annotated with explanatory information so they can easily explore and learn about different parts of their body.\r\n\r\nKlarismo is the only provider of MR analytics that can offer truly scalable analysis for large data collections. Cloud-based processing allows 1000s of acquisitions to be analyzed simultaneously. Machine learning techniques utilize Klarismo’s proprietary collection of labelled MRI data and eliminate the need for manual processing to produce precise volumetric measurements.\r\n\r\nKlarismo specializes in the detailed analysis of body composition, including volumetric measurements of different muscle and fat tissues, from whole-body acquisitions.", "one_liner": "Klarismo turns your body into an interactive experience. We built a…", "team_size": 10, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1430435618, "tags": [ "Health Tech", "Medical Devices" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2015", "status": "Inactive", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/klarismo", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2015/klarismo.json", "year_founded": 2014, "city": "San Francisco", "country": "US", "linkedin_url": "", "x_url": "", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/klarismo", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/9b735035a5d3492fb1057eb5b35bd5b80ee018df.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 71690, "full_name": "Marcus Foster", "title": "Founder/CEO", "founder_bio": "Founder and CEO at KAYMO and Klarismo (S15)\nPreviously led product teams at Google, Apple, GRAIL, Yahoo, and Q Bio.", "is_active": false, "linkedin_url": "https://www.linkedin.com/in/mafoster/", "x_url": "https://x.com/schlunzi", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/7f3d4cdd32ead30d6424f4233fdab8b4b87d66e6.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 962, "name": "Cofactor Genomics", "slug": "cofactor-genomics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/0138772cf18d9846bdac1578f7edd2288e7e4142.png", "website": "http://cofactorgenomics.com", "all_locations": "St. Louis, MO, USA", "long_description": "Cofactor uses RNA and Predictive Immune Modeling to build better biomarkers and improve patient outcomes.\r\n\r\nLed by Jarret Glasscock and a group of expert human genome scientists,Cofactor has built a new category of diagnostic technology powered by unique and powerful RNA data models built on terabytes of data. \r\n\r\nThe team recently had their technology validation peer-reviewed by the organizations that set standards for diagnostic technology (CAP, AMP) and is publishing in the Journal of Molecular Diagnostics. In addition, the team made news when Cancer Physicians who sit on the committee for patient treatment guidelines (NCCN) presented a clinical study using Cofactor’s technology showing superiority in predicting the patients who will respond to immunotherapy. This initial application is an acute problem recognized widely in the rapidly developing immunotherapy industry and represents north of a billion dollar TAM. \r\n\r\nAfter a number of recent key milestones, the team is taking the technology more broadly to 50% of cancers diagnosed in the US. \r\n\r\nCurrent investors include Menlo Ventures, DCVC, and Ascension Ventures (this last investor representing the funding arm for 13 National U.S. Healthcare Systems).", "one_liner": "Cofactor closes the precision medicine gap with predictive diagnostics", "team_size": 13, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1433394319, "tags": [ "Medical Devices", "Biotech", "Diagnostics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2015", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/cofactor-genomics", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2015/cofactor-genomics.json", "year_founded": 2015, "city": "St. Louis", "country": "US", "linkedin_url": "https://www.linkedin.com/company/cofactorgenomics/", "x_url": "https://twitter.com/cofactorgenomic", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/cofactor-genomics", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/0138772cf18d9846bdac1578f7edd2288e7e4142.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 93360, "full_name": "Dave Messina", "title": "Founder/COO", "founder_bio": "Dr. Dave Messina has over 25 years of experience in healthcare and has been leading healthcare investments at Pioneer Fund since 2019. He has led 100+ deals including top portfolio companies like Gilgamesh ($1B exit to Abbvie) and Assort Health ($500M+ valuation). Previously he founded the RNA and machine learning company Cofactor Genomics (YC S15) and led it to national Medicare reimbursement. Dr. Messina also worked on the Human Genome Project.", "is_active": false, "linkedin_url": "http://linkedin.com/in/davemessina", "x_url": "https://twitter.com/davemessina", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/ab073e2e48634af8f85e9039dd8a789ce8bfdee7.jpg" }, { "user_id": 93113, "full_name": "Jarret Glasscock", "title": "Founder/CTO", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/jarretglasscock", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/e79cc3d931002836ab378b3f801270df9fc3504c.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 1000, "name": "Loop Genomics", "slug": "loop-genomics", "former_names": [], "small_logo_thumb_url": "/company/thumb/missing.png", "website": "http://www.loopgenomics.com/", "all_locations": "San Francisco, CA, USA; San Jose, CA, USA", "long_description": "Loop Genomics provides long-read sequencing solutions across a diverse set of research and clinical applications. Our platform for long-read DNA sequencing transforms short-read DNA sequencers into long-read sequencing machines. ", "one_liner": "Novel long-read DNA sequencing technology", "team_size": 7, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1447280416, "tags": [ "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2016", "status": "Acquired", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/loop-genomics", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2016/loop-genomics.json", "year_founded": 2016, "city": "San Francisco", "country": "US", "linkedin_url": "", "x_url": "", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/loop-genomics", "github_url": null, "logo_url": null, "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 116430, "full_name": "Tuval Ben-Yehezkel", "title": "Founder/CEO", "founder_bio": "", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/tuval-ben-yehezkel-04608424", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/c6435b8c87088bc68324de7128b04f4a96f0a616.jpg" } ], "jobs": [], "news": [ { "title": "Element Biosciences Acquires Loop Genomics | GenomeWeb", "url": "https://www.genomeweb.com/business-news/element-biosciences-acquires-loop-genomics", "date": "Feb 08, 2022" } ], "launches": [] }, { "id": 1014, "name": "Luminist Labs", "slug": "luminist-labs", "former_names": [ "Luminist" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/b2a824d7b13f5cb87d6f2567fb9307570a0c1d46.png", "website": "http://luministlabs.com", "all_locations": "New York City, NY, USA", "long_description": "Luminist developed a non-invasive diagnostic test for the early detection and staging of liver fibrosis and non-alcoholic steatohepatitis (NASH). Luminist was acquired in 2020 by DiscernDx.", "one_liner": "Diagnostic platform for early detection of liver disease", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1447311916, "tags": [ "Medical Devices", "Diagnostics", "Genomics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2016", "status": "Acquired", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/luminist-labs", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2016/luminist-labs.json", "year_founded": 2015, "city": "New York City", "country": "US", "linkedin_url": "", "x_url": "", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/luminist", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/b2a824d7b13f5cb87d6f2567fb9307570a0c1d46.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 103004, "full_name": "Storm Stillman", "title": "Founder/CEO", "founder_bio": "Co-founder and CEO of Luminist Labs (Acquired by DiscernDx)\nCurrently CEO @ Curebase (S18)", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/ecoa", "x_url": "https://twitter.com/StormStillman", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/e18d2a6b6c07645bafa74bc626b5d56b949ed009.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 1023, "name": "Unima", "slug": "unima", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/6c2c011e4d98e07f268e9d5fe993f2508a4a51e7.png", "website": "http://www.unimadx.com", "all_locations": "Zapopan, Jal., Mexico", "long_description": "Unima developed a fast and low-cost diagnostic and real-time disease surveillance that allows anyone to diagnose a disease directly where the patient is, without using lab equipment, with results in 15 minutes and at a very low cost.", "one_liner": "Fast and low-cost diagnostics for real time disease surveillance", "team_size": 26, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1447312816, "tags": [ "Health Tech", "Biotech", "Diagnostics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2016", "status": "Inactive", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "Mexico", "Latin America" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/unima", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2016/unima.json", "year_founded": 2015, "city": "Zapopan", "country": "MX", "linkedin_url": "", "x_url": "https://twitter.com/Unimadx", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/unima", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/6c2c011e4d98e07f268e9d5fe993f2508a4a51e7.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 111968, "full_name": "Rodrigo Nuno", "title": "Founder", "founder_bio": "Founder on Unima. I worked on varios different aspects of the company. Was in change of manufacturing veterinary products, quality control, manufacturing, purchases, operations, contract manufacturing and IT. When we transition Unima from vet product to diagnostic, I continue working as head of manufacturing and started working as Director of engineering.\n\nAs Director of engineering I was in charge of insfrastructure, architecture, developing, hiring and all tasks related to a small team.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/rodrigo-nuno-585570a/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/4ec803dc3eac6ad54a4545c0ffbd4862d18434d3.jpg" }, { "user_id": 102097, "full_name": "Maria Laura Mendoza", "title": "Founder/CPO", "founder_bio": "", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/lauramendoza", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/c2360239475fd8f11b95ae5d74958215f3a0c497.jpg" }, { "user_id": 112393, "full_name": "Alejandro Nuño Ayala", "title": "Founder/R&D Director", "founder_bio": "", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/alejandronuno/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/2020ff0e8bb249bb6d887b5a80b36a2079ac7a94.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 1030, "name": "Opentrons", "slug": "opentrons", "former_names": [ "OpenTrons" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/218a1e71ef58cf5c6cbd797a5c9a25f5b4525037.png", "website": "http://opentrons.com", "all_locations": "New York City, NY, USA; New York, NY, USA", "long_description": "Today, biologists spend too much time pipetting by hand. We think biologists should have robots to do pipetting for them. People doing science should be free of tedious benchwork and repetitive stress injuries. They should be able to spend their time designing experiments and analyzing data.\r\n\r\nThat's why we started Opentrons.\r\n\r\nWe make robots for biologists. Our mission is to provide the scientific community with a common platform to easily share protocols and reproduce each other's results. Our robots automate experiments that would otherwise be done by hand, allowing our community to spend more time pursuing answers to some of the 21st century’s most important questions.", "one_liner": "We make robots for biologists. ", "team_size": 300, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1447527916, "tags": [ "Robotics", "Synthetic Biology", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2016", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/opentrons", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2016/opentrons.json", "year_founded": 2014, "city": "New York City", "country": "US", "linkedin_url": "", "x_url": "https://twitter.com/opentrons_", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/opentrons", "github_url": "https://github.com/Opentrons", "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/218a1e71ef58cf5c6cbd797a5c9a25f5b4525037.png", "app_video_url": null, "dday_video_url": null, "company_photos": [ "https://bookface-images.s3.us-west-2.amazonaws.com/attachments/7aa1cf28026cc428d3f325271eb20c1391aa1839.png" ], "primary_partner": null, "founders": [ { "user_id": 105840, "full_name": "Nicholas Wagner", "title": "Founder", "founder_bio": "I'm working on feeding Quant Research to Generative AI as a service.\n\nBA Mathematics - Lehigh University '05\nMS Analytical Finance - Lehigh University '08\nMBA Finance - University of Wisconsin-Madison Applied Security Analysis Program '12\n\nCo-founder - Opentrons Labware - MVP Software '13-16\n\n", "is_active": false, "linkedin_url": "https://www.linkedin.com/in/nicholashwagner", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/54cf64f9527299b19b692098a26925d879b974ce.jpg" }, { "user_id": 105743, "full_name": "Will Canine", "title": "Founder/CPO", "founder_bio": "", "is_active": false, "linkedin_url": "https://www.linkedin.com/in/will-canine-602a9266", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/77b5f65539c11bc54211d9f4b493b9cb9d2797fb.jpg" }, { "user_id": 107183, "full_name": "Chiu Chau", "title": "Founder", "founder_bio": null, "is_active": false, "linkedin_url": "https://www.linkedin.com/pub/chiu-chau/b/297/bb2", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/be84f368d30a128b249cd97a617c9b2dcc00518f.jpg" } ], "jobs": [], "news": [ { "title": "Biohackers tackle COVID testing and variants with robots - Los Angeles Times", "url": "https://www.latimes.com/world-nation/story/2021-10-15/biohackers-tackle-covid-testing-variants-with-robots", "date": "Oct 15, 2021" }, { "title": "SoftBank Invests in Robotics Company Behind NYC Covid Testing", "url": "https://www.bloomberg.com/news/articles/2021-09-23/softbank-invests-in-robotics-company-behind-nyc-covid-testing", "date": "Sep 23, 2021" } ], "launches": [] }, { "id": 1109, "name": "BillionToOne", "slug": "billiontoone", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/7374f48e30f2dabadb3413903af69fcda589d67f.png", "website": "https://www.billiontoone.com", "all_locations": "San Francisco, CA, USA; Menlo Park, CA, USA", "long_description": "BillionToOne has developed a DNA molecular counter that increases the cell-free DNA diagnostics resolution by over 1,000 fold, which unlocks transformative improvements in prenatal screening and liquid biopsy for cancers. Unity Screen, BillionToOne's commercially available non-invasive prenatal test (NIPT), is the only NIPT that can assess fetal risk for both recessive conditions and aneuploidies from maternal blood. UNITY Screen continues to grow exponentially and is on its path to becoming the next standard-of-care, with an increasing number of publications showing its accuracy and advantages over other screening methods. We have also recently used our molecular counting technology to develop liquid biopsy tests, which have the potential to completely transform oncology care.", "one_liner": "The genetic testing platform detecting and measuring disease.", "team_size": 300, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1453416611, "tags": [ "Diagnostics", "Genomics" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Summer 2017", "status": "Public", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/billiontoone", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2017/billiontoone.json", "year_founded": 2016, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/billiontoone/", "x_url": "https://twitter.com/billiontooneinc?lang=en", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/billiontoone", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/7374f48e30f2dabadb3413903af69fcda589d67f.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": { "name": "Jared Friedman", "url": "https://www.ycombinator.com/people/jared-friedman" }, "founders": [ { "user_id": 113037, "full_name": "Oguzhan Atay", "title": "Founder", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/oatay", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/bc8f1560f5c3e5e466f3af42f1115b49ae251798.jpg" }, { "user_id": 108548, "full_name": "David Tsao", "title": "Founder/CTO", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/davidtsao", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/ff881934f71e506851b4ce1720adb400b739d98b.jpg" } ], "jobs": [ { "id": 90768, "title": "Senior Software Engineer, Digital Experiences (Prenatal)", "url": "https://www.ycombinator.com/companies/billiontoone/jobs/9ZwkJry-senior-software-engineer-digital-experiences-prenatal", "location": "Menlo Park, CA, US", "type": "Full-time", "role": "Engineering", "role_type": "Full stack", "salary_range": "$190K - $211K", "equity_range": "", "experience": "6+ years", "visa": "US citizen/visa only", "skills": [ "Amazon Web Services (AWS)", "Django", "Python", "React", "TypeScript" ] }, { "id": 90769, "title": "Senior Software Engineer, Prenatal", "url": "https://www.ycombinator.com/companies/billiontoone/jobs/VT6hjtG-senior-software-engineer-prenatal", "location": "Menlo Park, CA, US", "type": "Full-time", "role": "Engineering", "role_type": "Backend", "salary_range": "$190K - $211K", "equity_range": "", "experience": "6+ years", "visa": "US citizen/visa only", "skills": [ "Amazon Web Services (AWS)", "Django", "Python", "React", "TypeScript", "Heroku", "Kafka" ] }, { "id": 93975, "title": "Senior AI Engineer I", "url": "https://www.ycombinator.com/companies/billiontoone/jobs/1dIzNNO-senior-ai-engineer-i", "location": "Menlo Park, CA", "type": "Full-time", "role": "Engineering", "role_type": "Full stack", "salary_range": "$174K - $201K", "equity_range": "", "experience": "3+ years", "visa": "Will sponsor", "skills": [] }, { "id": 97725, "title": "Director, Office of the CEO, Founder in Residence Program", "url": "https://www.ycombinator.com/companies/billiontoone/jobs/l1CWVry-director-office-of-the-ceo-founder-in-residence-program", "location": "Menlo Park, CA, US", "type": "Full-time", "role": "Operations", "role_type": null, "salary_range": "$204K - $225K", "equity_range": "100.00%", "experience": "6+ years", "visa": "US citizen/visa only", "skills": [] } ], "news": [ { "title": "Molecular Diagnosis Firm BillionToOne Raises $273 Million in IPO - Bloomberg", "url": "https://www.bloomberg.com/news/articles/2025-11-06/molecular-diagnosis-firm-billiontoone-raises-273-million-in-ipo?taid=690c18284571d00001b66ed2&utm_campaign=trueanthem&utm_content=business&utm_medium=social&utm_source=twitter", "date": "Nov 05, 2025" }, { "title": "Diagnostics Firm BillionToOne Files for US IPO Despite Shutdown - Bloomberg", "url": "https://www.bloomberg.com/news/articles/2025-10-07/diagnostics-firm-billiontoone-files-for-us-ipo-despite-shutdown", "date": "Oct 07, 2025" }, { "title": "BillionToOne raises $130M at $1B-plus valuation for precision diagnostics", "url": "https://www.axios.com/pro/health-tech-deals/2024/06/21/billiontoone-130m-series-d-1b-valuation-precision-diagnostics", "date": "Jun 21, 2024" }, { "title": "BillionToOne Closes $125M Series C Funding with Premier Global Investors", "url": "https://www.linkedin.com/feed/update/urn:li:activity:6914924371232854017/", "date": "Mar 30, 2022" } ], "launches": [] }, { "id": 1235, "name": "Shield Bio", "slug": "shield-bio", "former_names": [ "TL Biolabs", "Shield Diagnostics" ], "small_logo_thumb_url": "/company/thumb/missing.png", "website": "http://shieldbio.com", "all_locations": "San Francisco, CA, USA; San Jose, CA, USA", "long_description": "Shield Bio is a precision medicine company with a\r\nproprietary platform that enables reliable nanopore\r\nsequencing in under a minute, in a clinical setting. It is\r\nfocused on bringing 3rd generation or \"nanopore\"\r\nsequencing into clinical use to deliver on the promise of\r\nprecision medicine. Shield is initially using the technology to\r\nimprove the treatment of infectious disease and address the\r\nunmet clinical need of sepsis, which kills 300,000 people a\r\nyear in the US alone.", "one_liner": "Bringing 3rd generation, nanopore sequencing to healthcare to solve…", "team_size": 28, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1461210620, "tags": [ "Healthcare", "Genomics", "Nanotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2016", "status": "Inactive", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/shield-bio", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2016/shield-bio.json", "year_founded": null, "city": "San Francisco", "country": "US", "linkedin_url": null, "x_url": "", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/tl-biolabs", "github_url": null, "logo_url": null, "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 135686, "full_name": "Fred Turner", "title": "Founder/CEO", "founder_bio": "", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/fred-turner-70688776", "x_url": "https://twitter.com/FredTurnerBio", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/24846d3e66271106d7d5d967ea6f89429cc7313c.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 1243, "name": "Kenota (formerly ExVivo Labs)", "slug": "kenota", "former_names": [ "ExVivo Labs" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/7e389cbf09ff94eb9242f60bd9522b162a2464ff.png", "website": "https://kenota.com/", "all_locations": "Kitchener, ON, Canada", "long_description": "", "one_liner": "Kenota is revolutionizing the way we test for disease ", "team_size": 35, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1461643818, "tags": [ "Healthcare", "Diagnostics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2016", "status": "Inactive", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "Canada", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/kenota", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2016/kenota.json", "year_founded": 2014, "city": "Kitchener", "country": "CA", "linkedin_url": "https://www.linkedin.com/company/kenotahealth", "x_url": "https://twitter.com/KenotaHealth", "fb_url": "https://www.facebook.com/KenotaHealth/?ref=py_c", "cb_url": "https://www.crunchbase.com/organization/exvivo-labs", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/7e389cbf09ff94eb9242f60bd9522b162a2464ff.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 137714, "full_name": "Moufeed Kaddoura", "title": "Founder/CEO", "founder_bio": "CEO at Ranata Therapeutics\nPre. Founder at Kenota Health", "is_active": false, "linkedin_url": "https://www.linkedin.com/in/moufeed/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/7c531610ae6056da18c036c0b235cfa569b5ae1e.jpg" }, { "user_id": 138552, "full_name": "Eric Blondeel", "title": "Founder/CTO", "founder_bio": "Co-Founder, formerly at Samos Insurance (W22).\n\nCo-Founder, formerly at Kenota Health (S16) (formerly ExVivo Labs).", "is_active": false, "linkedin_url": "https://ca.linkedin.com/in/eric-blondeel-b797023", "x_url": "https://twitter.com/EricJMBlondeel", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/4fad3f16886f87ca4f7120710c2e3dbdfdca9426.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 1491, "name": "InnaMed", "slug": "innamed", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/5a5f04ad2b7ba3169c85be1ac62f4a434b27d75d.png", "website": "http://www.InnaMed.com", "all_locations": "San Francisco, CA, USA; Philadelphia, PA, USA", "long_description": "InnaMed's HomeLab device and software take the hassle out of blood testing and let you access precision medical care from the comfort and privacy of your home. Healthcare providers and researchers can now receive timely clinical reports that they are accustomed to interpreting directly to their EMR, LIMS or EDC system. Trend identification and pattern matching software can guide decision making in the prescription and dosing of therapy and deep integration with the healthcare system and telehealth services allows for data driven care while also ensuring human connection.\r\n\r\n\r\n", "one_liner": "At-home blood testing: measure + analyze + enhance.", "team_size": 7, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1478225435, "tags": [ "Biotech", "Digital Health", "Telemedicine" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2017", "status": "Inactive", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/innamed", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2017/innamed.json", "year_founded": 2016, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/innamed", "x_url": "https://twitter.com/InnaMed_Inc", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/innamed", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/5a5f04ad2b7ba3169c85be1ac62f4a434b27d75d.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 161842, "full_name": "Anup Singh", "title": "Founder/Chief Scientific Officer", "founder_bio": "", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/anup-singh-229678b3", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/e7314a17a2bd4ce92f872cfa84b6324c384b9e5e.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 1532, "name": "Delee", "slug": "delee", "former_names": [ "Semka Technologies" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/badd1b077ec76be8053aae9a5daf9d6f1afd8d56.png", "website": "http://www.delee.co ", "all_locations": "Monterrey, N.L., Mexico", "long_description": "Delee is a medical device company that developed a blood-testing device for early diagnosis of cancer and treatment monitoring through the isolation and analysis of the circulating tumor cells. ", "one_liner": "Blood testing device for early diagnosis of cancer and treatment…", "team_size": 18, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1478742617, "tags": [ "Medical Devices", "Diagnostics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2017", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "Mexico", "Latin America" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/delee", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2017/delee.json", "year_founded": 2017, "city": "Monterrey", "country": "MX", "linkedin_url": "https://www.linkedin.com/company/35691474", "x_url": "https://twitter.com/deleecorp", "fb_url": "https://www.facebook.com/DeleeCorp/", "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/badd1b077ec76be8053aae9a5daf9d6f1afd8d56.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 146653, "full_name": "Liza Velarde", "title": "Founder", "founder_bio": "Co-Founder and acting CEO at Delee Corp. Velarde has been responsible for the development and execution of the company's strategic plans. Velarde's outstanding work has been highly regarded by international institutions such as Cartier Women's Initiative Awards and WeXchange (from the Inter-American Development Bank). She also lead and supervised the development of the Zen FluidicsTM scientific line, a group of products that enables researchers to develop their own microfluidic applications. ", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/lizavelarde/", "x_url": "https://twitter.com/liza_velarde21", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/3fc7f37e65c672c0830a8b4317008838a8ddebde.jpg" }, { "user_id": 162876, "full_name": "Alejandro Abarca-Blanco", "title": "Founder", "founder_bio": null, "is_active": true, "linkedin_url": "https://linkedin.com/in/alejandroabarca", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/5cb50dbc32e479e507c7d69201bd6b7bf5c9ed56.jpg" }, { "user_id": 161991, "full_name": "Juan Felipe Yee De León", "title": "Founder", "founder_bio": null, "is_active": true, "linkedin_url": "https://mx.linkedin.com/in/juan-felipe-yee-55107a5b", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/85a63ebcc27be009e3e88f32a8a52c7ade4a94e9.jpg" } ], "jobs": [], "news": [ { "title": "52 Women-Led Startups Driving The Future Of HealthTech And FemTech", "url": "https://www.forbes.com/sites/allysonkapin/2021/06/24/52-women-led-startups-driving-the-future-of-healthtech-and-femtech/?sh=53aee317107c", "date": "Oct 06, 2021" } ], "launches": [] }, { "id": 1610, "name": "Darmiyan", "slug": "darmiyan", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/3be6f1febb81bc5a98e11a2a64bc294e0cee4eff.png", "website": "https://www.darmiyan.com/", "all_locations": "San Francisco, CA, USA", "long_description": "Novel quantitative virtual microscopy for early detection of Alzheimer's disease from non-invasive MRI.", "one_liner": "Early detection of Alzheimer's disease", "team_size": 8, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1493265720, "tags": [ "Machine Learning", "Health Tech", "Diagnostics", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2017", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/darmiyan", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2017/darmiyan.json", "year_founded": null, "city": "San Francisco", "country": "US", "linkedin_url": "", "x_url": "", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/darmiyan", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/3be6f1febb81bc5a98e11a2a64bc294e0cee4eff.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 188008, "full_name": "Padideh Kamali-Zare", "title": "Founder", "founder_bio": "I'm Padideh — brain enthusiast, data driven, and one of the brains behind Darmiyan. After my Ph.D. in Biological Physics from KTH (Sweden) and postdoc in computational neuroscience at NYU (New York), I dove headfirst into the startup world to tackle a cause close to my heart: Alzheimer's. I've been on a mission to outsmart this disease since my grandmother's diagnosis. BrainSee is our first product that catches Alzheimer's early and give people a fighting chance. ", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/padideh/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/a3b3194ecf38f9c4d1a73efa8fa272cbfdff129f.jpg" }, { "user_id": 131881, "full_name": "Kaveh Vejdani", "title": "Founder/Chief Medical and Technology Officer", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/kaveh-vejdani-5369561", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/c75aa5ac5e434a7989fa3e497f0457471346a8f4.jpg" } ], "jobs": [], "news": [ { "title": "FDA clears AI that predicts Alzheimer’s progression from an MRI scan", "url": "https://www.fiercebiotech.com/medtech/fda-clears-ai-predicts-alzheimers-progression-mri-scan", "date": "Jan 12, 2024" } ], "launches": [] }, { "id": 1646, "name": "Rev Genomics", "slug": "rev-genomics", "former_names": [ "Rev Genomics", "Inc." ], "small_logo_thumb_url": "/company/thumb/missing.png", "website": "https://www.revgenomics.com", "all_locations": "San Francisco, CA, USA; Oakland, CA, USA", "long_description": "Rev Genomics is a plant biotechnology company that provides breeders, growers, and retailers with novel cultivars to differentiate themselves in high value markets.", "one_liner": "Rev is a biotechnology company creating better plants.", "team_size": 8, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1493697720, "tags": [ "B2B" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Summer 2017", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/rev-genomics", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2017/rev-genomics.json", "year_founded": 2016, "city": "San Francisco", "country": "US", "linkedin_url": "", "x_url": "", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/rev-genomics", "github_url": null, "logo_url": null, "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 38368, "full_name": "Bertrand Vick", "title": "Founder/CEO", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/bertrand-vick-4056044?trk=hp-identity-photo", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/9d90c8fc0d4a3921faf7c8b312eef0216b47713c.jpg" } ], "jobs": [ { "id": 44028, "title": "Rev Genomics (S17) seeks plant biologist", "url": "https://www.ycombinator.com/companies/rev-genomics/jobs/klDv8Bo-rev-genomics-s17-seeks-plant-biologist", "location": "oakland, ca", "type": "Full-time", "role": "Science", "role_type": "Biotechnology", "salary_range": "", "equity_range": "", "experience": "Any (new grads ok)", "visa": "US citizen/visa only", "skills": [] } ], "news": [], "launches": [] }, { "id": 1655, "name": "PreDxion Bio", "slug": "predxion-bio", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/519a74fb089a6c9dd854328b8022c68e00467972.png", "website": "http://www.predxionbio.com", "all_locations": "San Francisco, CA, USA; South San Francisco, CA, USA", "long_description": "PreDxion Bio is working on a rapid saliva-based antigen test for the detection of SARS-CoV-2 S-protein in asymptomatic and presymptomatic patients. Our technology is uniquely capable of being scaled to 10's of millions of tests of days using semiconductor fab processes, a scale of testing necessary to better inform public health officials and policymakers and enable contact tracing at scale.\r\n\r\nPreDxion Bio's origins are in critical care: our original technology is a rapid, near real-time cytokine and biomarker detection platform to monitor the immune response of critically-ill patients. This technology leverages a novel sensor platform we spun out of the University of Michigan. PreDxion Bio has received FDA Breakthrough Device designation and partnered with top pharmcos to monitor the immune response following CAR-T therapy and predict the development of cytokine release syndrome and neurological AEs, and for use in guiding precision medicine approaches in critical care.", "one_liner": "Rapid, scalable diagnostic for SARS-CoV-2 and beyond", "team_size": 6, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1493740320, "tags": [ "Microfluidics", "Nanosensors", "COVID-19" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2017", "status": "Inactive", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/predxion-bio", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2017/predxion-bio.json", "year_founded": 2017, "city": "San Francisco", "country": "US", "linkedin_url": "", "x_url": "", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/predxion-bio", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/519a74fb089a6c9dd854328b8022c68e00467972.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 177079, "full_name": "Walker McHugh", "title": "Founder", "founder_bio": "Walker is Co-founder and CEO of PreDxion Bio. Walker is a graduate of the University of Michigan, completing undergraduate studies in immunology and further graduate training in the Medical Product Development Program at the University of Michigan College of Engineering. Walker is a past Fellow in the Zell Global Entrepreneurship Program, was named the 2017 University of Michigan Graduate Student Entrepreneur of the Year, and a Top 20 Entrepreneur Alumni from the University of Michigan in 2019.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/walker-mchugh-517b86b7/", "x_url": "https://twitter.com/walker_mchugh?s=21&t=mXbPwUBOPCQgoonxNjWP9Q", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/7cee81f1d491872842f5f99808020ac799156b1e.jpg" }, { "user_id": 191741, "full_name": "Timothy Cornell", "title": "Founder", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/timothy-cornell-64a19145", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/24a383dd4375534598881f133d0e379052f959e1.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 1665, "name": "Oncobox", "slug": "oncobox", "former_names": [ "Oncobox", "OncoBox" ], "small_logo_thumb_url": "/company/thumb/missing.png", "website": "http://oncobox.com", "all_locations": "Walnut, CA, USA", "long_description": "Oncobox believes that many late-stage cancer patients are dying prematurely because doctors lack a data-driven tool to help them decide which drugs currently on the market would most effectively fight individual patients’ specific cancers. That’s where Oncobox comes in. Oncobox is low-cost personalized genetic profiling to help doctors decide which drug to use. In a recent study conducted by leading cancer researchers in Europe and Asia on 900 patients with various late-stage cancers, Oncobox increased the effectiveness of targeted therapies from 25% to 64%.\r\n\r\nHow does Oncobox work? Over 150 targeted cancer drugs are currently on the market. But deciding which of these drugs to give to late-stage cancer patients is not a simple task. Cancer doctors are in a race against the clock. They don’t always know which medication will be most effective for their patients. Because these drugs are expensive and typically have significant side effects, they can’t just try them all. Because of these barriers, targeted cancer therapies are effective only 25% of the time, and 70% of patients with late-stage cancers die due to the toxic side effects of ineffective drugs.\r\n\r\nOncobox Dx analyses tumor DNA, RNA, and molecular pathways using algorithms to distinguish which molecular targets are the most crucial for individual cases. Doctors receive a clinically actionable report that shows them which drugs are likely to be most effective on the patient.\r\n\r\nWe actively seek partners from pharma, hospitals/clinicians, payers, and genomic centers. Feel free to contact us at hello@oncobox.com. \r\n\r\nOur team and the scientific advisory board consisting of leading scientists and researchers from UCLA, Stanford, Johns Hopkins University, Boston University, Tufts University, and Rutgers University.", "one_liner": "Finding the right cancer drug for each patient. ", "team_size": 11, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1493851252, "tags": [ "Drug discovery", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2017", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/oncobox", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2017/oncobox.json", "year_founded": null, "city": "Walnut", "country": "US", "linkedin_url": "", "x_url": "", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/oncobox", "github_url": null, "logo_url": null, "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 187287, "full_name": "Andrew Garazha", "title": "Founder/CEO", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/garazha/", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/b2fe9db2ae1be10198b1053682fb59ad55e404d0.jpg" }, { "user_id": 189703, "full_name": "Anton Buzdin", "title": "Founder/CSO", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/anton-buzdin-8284972", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/645b94e854eaa634f8ab2e93480e9e5f87488952.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 1686, "name": "Cambridge Cancer Genomics", "slug": "cambridge-cancer-genomics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/53b0518d38ef7cc187360951dee976ad809db1d9.png", "website": "http://ccg.ai", "all_locations": "Cambridge, England, United Kingdom; England, United Kingdom", "long_description": "CCG.ai exist to ensure that each patient has the right drug, at the right time, to beat their cancer.\r\n‍\r\nWe build the software to enable data-driven precision oncology and systematically develop data-driven biomarkers indicative of treatment response. We believe that increasing amounts of clinical and genomic data have the potential to transform cancer treatment, and enable oncologists to make smarter decisions about which drug to use in which circumstance.\r\n\r\nWe are expanding our team in Cambridge, UK, offering a fantastic opportunity for dedicated individuals who are comfortable in a high-work high-reward environment, and who are enthusiastic for a dynamic and varied role. We are looking for people who fit well into our team and company culture, and who like to overcome challenges and drive the business forward. In exchange, we offer a competitive salary with performance related bonuses and stock options, alongside excellent career development opportunities in a fast-growing start-up with a chance to truly impact how cancer is treated.\r\n\r\nTo apply, please send your CV to info@ccg.ai", "one_liner": "CCG.ai empowers clinicians to make personalised treatment strategies…", "team_size": 25, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1495670432, "tags": [ "Genomics", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2017", "status": "Inactive", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United Kingdom", "Europe" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/cambridge-cancer-genomics", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2017/cambridge-cancer-genomics.json", "year_founded": 2015, "city": "Cambridge", "country": "GB", "linkedin_url": "", "x_url": "https://twitter.com/CCGenomics", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/cambridge-cancer-genomics", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/53b0518d38ef7cc187360951dee976ad809db1d9.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 195460, "full_name": "John Cassidy", "title": "Founder/CEO", "founder_bio": "", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/john-w-cassidy", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/a09fdd7c7663987872a89785ed555287191901ac.jpg" }, { "user_id": 195868, "full_name": "Nirmesh Patel", "title": "Founder/Chief Scientific Officer", "founder_bio": "Scientist turned founder, trying to solve big problems and change the world!", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/nirmesh-patel/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/b95c957e6f36186997453224da349f1becbf6b67.jpg" }, { "user_id": 195908, "full_name": "Evaline Tsai", "title": "Founder/CPO", "founder_bio": "", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/evaline-tsai-710b4386/", "x_url": "https://twitter.com/EvalineTsai", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/173c1510360021a6c88f401105de6a0a5c7df4aa.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 1791, "name": "Correlia Biosystems", "slug": "correlia-biosystems", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/d9aad85e9ea2a3b4df72a9807d29b7536bcb76ce.png", "website": "http://www.correliabio.com", "all_locations": "San Francisco, CA, USA; Berkeley, CA, USA", "long_description": "Correlia Biosystems is a UC Berkeley spinoff company based in Berkeley, CA. Correlia develops innovative microscale tools that accelerate rapid quantification of biomolecules.\r\n\r\nOur versatile \"SimpleScan\" technology opens up new biological questions from one microliter of sample, with rapid results that allow for dynamic monitoring of protein expression profiles (rather than simple end-point measurement). Applications range from enabling next-gen proteomic data sets to point-of-care diagnostics.", "one_liner": "Next-gen blood testing to provide 1000x more data to pharma companies", "team_size": 16, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1510027355, "tags": [ "Hardware", "Lab-on-a-chip", "Microfluidics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2018", "status": "Inactive", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/correlia-biosystems", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2018/correlia-biosystems.json", "year_founded": null, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/8775625", "x_url": "", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/correlia-biosystems", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/d9aad85e9ea2a3b4df72a9807d29b7536bcb76ce.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 182024, "full_name": "Akwasi Apori", "title": "Founder", "founder_bio": "", "is_active": false, "linkedin_url": "https://www.linkedin.com/in/akwasi-apori-465b5211/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/aead751f8c7e0367eb128f8f71a16b8255cc7f2f.jpg" }, { "user_id": 221094, "full_name": "Kursad Araz", "title": "Founder/CTO", "founder_bio": null, "is_active": false, "linkedin_url": "https://www.linkedin.com/in/kursadaraz", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/67065f7e4c3f0fc03e853b3aa16cfb48bb290473.jpg" }, { "user_id": 221016, "full_name": "Samuel Tia", "title": "Founder", "founder_bio": null, "is_active": false, "linkedin_url": "https://www.linkedin.com/in/samtia/", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/de81784e531e00400bebab8b65511031d0328690.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 1916, "name": "Data Driven Bioscience", "slug": "data-driven-bioscience", "former_names": [], "small_logo_thumb_url": "/company/thumb/missing.png", "website": "http://datadrivenbioscience.com", "all_locations": "Durham, NC, USA", "long_description": "", "one_liner": "Cancer Diagnosis 10X faster, 10X cheaper", "team_size": 10, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1524711770, "tags": [ "Biotech", "Healthcare", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Summer 2018", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": [ { "question": "Describe what your company does in 50 characters or less.", "answer": "Cancer diagnosis 10X faster and 10X cheaper" } ], "question_answers": null, "url": "https://www.ycombinator.com/companies/data-driven-bioscience", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2018/data-driven-bioscience.json", "year_founded": 2018, "city": "Durham", "country": "US", "linkedin_url": "https://www.linkedin.com/in/sandeep-dave-439679165/", "x_url": "", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/data-driven-bioscience", "github_url": null, "logo_url": null, "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 236773, "full_name": "Sandeep Dave", "title": "Founder", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/sandeep-dave-439679165", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/a3af827406c62207803d154a6bbd849741f4d18c.jpg" } ], "jobs": [ { "id": 35229, "title": "Bioinformatics/Biostatistics specialist", "url": "https://www.ycombinator.com/companies/data-driven-bioscience/jobs/ZmjukEWRX-bioinformatics-biostatistics-specialist", "location": "Durham, North Carolina (Remote okay) / Remote", "type": "Full-time", "role": "Engineering", "role_type": "Data science", "salary_range": "$140K - $200K", "equity_range": "", "experience": "Any (new grads ok)", "visa": "Will sponsor", "skills": [ "Python", "R" ] } ], "news": [], "launches": [] }, { "id": 1932, "name": "Radix Labs", "slug": "radix-labs", "former_names": [ "Phloem biotech" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/0cac41291118dec8729ffc4b179a57d24f1c93ac.png", "website": "http://radix.bio", "all_locations": "Boston, MA, USA; Cambridge, MA, USA", "long_description": "", "one_liner": "Operating systems for biology labs", "team_size": 7, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1524873814, "tags": [ "IoT", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2018", "status": "Inactive", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/radix-labs", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2018/radix-labs.json", "year_founded": 2017, "city": "Boston", "country": "US", "linkedin_url": "", "x_url": "", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/radixlabs", "github_url": "https://github.com/radixbio", "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/0cac41291118dec8729ffc4b179a57d24f1c93ac.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 210182, "full_name": "Dhasharath Shrivathsa", "title": "Founder", "founder_bio": "founder of radix labs (YC S18) — operating systems for biology labs", "is_active": false, "linkedin_url": "https://www.linkedin.com/in/dhash-shrivathsa-52b7671a8", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/1ca67db312ca109f294aaba4715dedb63a077319.jpg" }, { "user_id": 250315, "full_name": "Ian Paul", "title": "Founder", "founder_bio": "", "is_active": false, "linkedin_url": "https://www.linkedin.com/in/ian-paul", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/80930d342755f76898fd8fccdfb059af18dd7c15.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 1933, "name": "Clear Gene", "slug": "clear-gene", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/4c3988b74387b722e9f7364d78e224dbb7a5e2f7.png", "website": "https://cleargene.com", "all_locations": "San Francisco, CA, USA; San Carlos, CA, USA", "long_description": "", "one_liner": "Our tests help eradicate cancer by telling doctors whether they got…", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1616188654, "tags": [ "Healthcare", "Diagnostics", "Women's Health", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2018", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/clear-gene", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2018/clear-gene.json", "year_founded": null, "city": "San Francisco", "country": "US", "linkedin_url": "", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/4c3988b74387b722e9f7364d78e224dbb7a5e2f7.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 107443, "full_name": "Brandon Steelman", "title": "Founder", "founder_bio": "", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/brandonsteelman", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/dbfac65ce0120ecccc44ed6193892fdbf0d412c3.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 1949, "name": "Scanwell Health", "slug": "scanwell-health", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/c239150be35c09cf1a917f12c84d7db6f28a85a6.png", "website": "https://www.scanwellhealth.com", "all_locations": "Los Angeles, CA, USA; Remote", "long_description": "Scanwell Health makes healthcare more accessible through smartphone-enabled, at-home diagnostics. Scanwell's innovative approach lets people test from anywhere, skip the waiting room and get same-day results. By quickly diagnosing acute illnesses, chronic diseases and rare conditions, Scanwell accelerates the path to treatment. Our first product is the only FDA-cleared over-the-counter app that provides testing and treatment for urinary tract infections (UTIs).", "one_liner": "Smartphone-enabled, at-home diagnostics", "team_size": 13, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1525226775, "tags": [ "Health Tech", "Diagnostics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2018", "status": "Acquired", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Fully Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/scanwell-health", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2018/scanwell-health.json", "year_founded": 2018, "city": "Los Angeles", "country": "US", "linkedin_url": "https://www.linkedin.com/company/scanwellhealth", "x_url": "https://twitter.com/scanwellhealth", "fb_url": "https://www.facebook.com/scanwellhealth/", "cb_url": "https://www.crunchbase.com/organization/scanwell-health", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/c239150be35c09cf1a917f12c84d7db6f28a85a6.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 247756, "full_name": "Stephen Chen", "title": "Founder/Founding CEO", "founder_bio": "", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/stephenlchen/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/9293be56a5f7229d89ab1f28e97df271e1b06ee8.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 2003, "name": "Eden", "slug": "eden-2", "former_names": [ "Higia", "Inc.", "Higia", "Eva Tech", "Eva Center" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/e9ed624456ba1fbda4567d62416d80343145cd4d.png", "website": "https://edenmed.com", "all_locations": "San Francisco, CA, USA", "long_description": "\r\nWe create the infrastructure and frontier AI that turn diagnostic data into precise clinical answers.\r\n\r\nOur Diagnostic OS supports the care of more than one patient every two seconds across 2,800+ healthcare systems in 20 countries.\r\n\r\nWe believe medicine is humanity’s most sacred work and we build the tools it deserves: Tools for Miracles.\r\n", "one_liner": "Building Clinical Superintelligence.", "team_size": 100, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1525846177, "tags": [ "Digital Health", "Healthcare", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Summer 2018", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/eden-2", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2018/eden-2.json", "year_founded": null, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/edenmedicalglobal/", "x_url": "https://twitter.com/evacenter_mx", "fb_url": "https://x.com/edenmed_ai", "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/e9ed624456ba1fbda4567d62416d80343145cd4d.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 173301, "full_name": "Julián Cantú", "title": "Founder/Co-Fundador, CEO", "founder_bio": "After his mother's painful three-time battle with cancer, Julián Ríos resolved to save lives through developing exceptional products that improve healthcare for everyone. \n\nCurrently, he is the CEO and Co-founder of Eden (edenmed.com), the leading radiology and imaging platform in Latinamerica. Eden creates tools that make radiology and imaging based diagnosis extremely precise and significantly more productive. \n\nIn 2018 Eden (formerly Eva) was named one of the 30 most promising businesses by F", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/juli%C3%A1n-r%C3%ADos-cant%C3%BA-903b76106/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/079c4909c0da14d34c555fa24a0c3727a69a75a4.jpg" }, { "user_id": 211703, "full_name": "Raymundo Gonzalez", "title": "Founder/CTO", "founder_bio": "Skilled in complex problem solving and in communicating with others. I am persistent working both individually and in teams. I always bring with me an innovation mindset, and a desire to make a difference for people. I am interested in technology, entrepreneurship, and engineering. ", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/raymundo-gzz/", "x_url": "https://twitter.com/RaymundoGzz19", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/77697afcdcf8350aaf77a2b3ccf9942580d7fd13.jpg" } ], "jobs": [ { "id": 93644, "title": "Member of Technical Staff, AI Research – Radiology Foundation Model", "url": "https://www.ycombinator.com/companies/eden-2/jobs/6PuixMH-member-of-technical-staff-ai-research-radiology-foundation-model", "location": "San Francisco, CA, US", "type": "Full-time", "role": "Science", "role_type": "Research", "salary_range": "$150K - $320K", "equity_range": "0.10% - 1.00%", "experience": "3+ years", "visa": "Will sponsor", "skills": [] } ], "news": [ { "title": "Eden raises $10M to address global radiologist shortage", "url": "https://www.axios.com/pro/health-tech-deals/2024/07/17/eden-10-million-radiology", "date": "Jul 17, 2024" }, { "title": "Mexican platform advances digital diagnostics in Latin America | Financial Times", "url": "https://www.ft.com/content/90564d73-8268-4160-8201-baa7140d143e", "date": "Jan 30, 2022" } ], "launches": [] }, { "id": 11976, "name": "BrainKey", "slug": "brainkey", "former_names": [ "Brain Key" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/37ef137c0b25704bcbf6c8a2e9e8910944567fe6.png", "website": "https://www.brainkey.ai/", "all_locations": "San Francisco, CA, USA", "long_description": "BrainKey is an AI-driven digital healthcare company with a mission to create a world free from dementia. ", "one_liner": "Brain Longevity", "team_size": 20, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1541131379, "tags": [ "Neurotechnology", "Health Tech", "Digital Health", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2019", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/brainkey", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2019/brainkey.json", "year_founded": 2018, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/brainkeyai/", "x_url": "https://twitter.com/BrainkeyAI", "fb_url": "https://www.facebook.com/BrainKeyAI/", "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/37ef137c0b25704bcbf6c8a2e9e8910944567fe6.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 286788, "full_name": "Owen Phillips, PhD", "title": "Founder", "founder_bio": "Stanford-trained entrepreneur and neuroscientist. \nhttps://owenphillips.com/\n\n\n", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/owenrobertphillips/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/4883905975aaf5b2009bec28947cd09431f3a8cd.jpg" } ], "jobs": [], "news": [ { "title": "Can we change how our brains age? Scientists think it’s possible", "url": "https://www.bbc.com/news/articles/c0www3qvx2zo", "date": "Sep 15, 2024" }, { "title": "How to protect your brain from ageing", "url": "https://www.bbc.com/reel/video/p0jdh8px/how-to-protect-your-brain-from-ageing", "date": "Sep 12, 2024" } ], "launches": [] }, { "id": 12036, "name": "Probably Genetic", "slug": "probably-genetic", "former_names": [ "Aiwa Health" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/9558e9a7114240a3f1e2a6378bd906ffe21826f3.png", "website": "https://www.probablygenetic.com/", "all_locations": "San Francisco, CA, USA", "long_description": "Probably Genetic is changing the lives of patients living with severe, complex diseases. Our data platform is used by drug developers and patient advocacy groups to develop and launch treatments for these patients. Our technology discovers undiagnosed patients online, analyzes their disease state using machine learning and at-home testing, and enables compliant communication with patients. In doing so, we help patients access diagnoses, clinical trials, and treatments as early as possible.", "one_liner": "Patient Intelligence Platform for Genetic Disease ", "team_size": 17, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1541561609, "tags": [ "Health Tech", "Biotech", "Genomics", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Winter 2019", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/probably-genetic", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2019/probably-genetic.json", "year_founded": 2019, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/probablygenetic/", "x_url": "", "fb_url": "https://www.facebook.com/ProbablyGenetic/", "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/9558e9a7114240a3f1e2a6378bd906ffe21826f3.png", "app_video_url": null, "dday_video_url": null, "company_photos": [ "https://bookface-images.s3.us-west-2.amazonaws.com/attachments/3444e0738890168924b0ade38090a2fcb410e03f.png" ], "primary_partner": null, "founders": [ { "user_id": 272136, "full_name": "Lukas Lange", "title": "Founder", "founder_bio": "CEO & Co-Founder of Probably Genetic. Previously BCG & The Bill & Melinda Gates Foundation. PhD from Oxford as a Rhodes Scholar.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/lukas-lange-8b1aa334/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/a34d08ca7bd7d5ef817d25623cafb18ffa6f5ba1.jpg" } ], "jobs": [ { "id": 96645, "title": "Director of Strategic Partnerships", "url": "https://www.ycombinator.com/companies/probably-genetic/jobs/Q6sRPPm-director-of-strategic-partnerships", "location": "San Francisco / Remote (US)", "type": "Full-time", "role": "Sales", "role_type": null, "salary_range": "", "equity_range": "", "experience": "5+ years", "visa": "US citizen/visa only", "skills": [] }, { "id": 96647, "title": "Forward Deployed Product Manager", "url": "https://www.ycombinator.com/companies/probably-genetic/jobs/KPPjdYB-forward-deployed-product-manager", "location": "San Francisco", "type": "Full-time", "role": "Product", "role_type": null, "salary_range": "", "equity_range": "", "experience": "5+ years", "visa": "US citizen/visa only", "skills": [] } ], "news": [ { "title": "Probably Genetic raises $12M to scale rare disease dataset, support drug discovery", "url": "https://www.fiercehealthcare.com/health-tech/probably-genetic-raises-12m-scale-rare-disease-dataset-support-drug-discovery", "date": "Oct 14, 2026" } ], "launches": [] }, { "id": 12077, "name": "Instapath Inc.", "slug": "instapath-inc", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/edbfa875f5b9593c4bbe89349b05b7a77c4bb9d6.png", "website": "http://instapathbio.com", "all_locations": "Houston, TX, USA", "long_description": "", "one_liner": "We built the world's first automated digital pathology lab.", "team_size": 6, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1541646306, "tags": [ "Medical Devices" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2019", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/instapath-inc", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2019/instapath-inc.json", "year_founded": 2017, "city": "Houston", "country": "US", "linkedin_url": "", "x_url": "https://twitter.com/instapathbio", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/instapath-inc", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/edbfa875f5b9593c4bbe89349b05b7a77c4bb9d6.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 222957, "full_name": "Mei Wang", "title": "Founder", "founder_bio": "I am the co-founder and CEO of Instapath Inc. ", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/mei-wang-34096858/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/a46d436fbef6131dca564b54b147ba120a05f5e3.jpg" }, { "user_id": 290685, "full_name": "Quincy Brown", "title": "Founder", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/j-quincy-brown-28b4288/", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/c0a44b468f8e9d9fd6b786a3b5b8db9e6b3760da.jpg" }, { "user_id": 288938, "full_name": "David Tulman", "title": "Founder", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/david-tulman-2aa38112a/", "x_url": null, "avatar_thumb_url": "/avatars/thumb/missing.png" } ], "jobs": [], "news": [], "launches": [] }, { "id": 12124, "name": "XGenomes", "slug": "xgenomes", "former_names": [ "XGenomes Corp." ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/4cca3d33a3a643c65629ce3164548e924340e550.png", "website": "http://www.xgenomes.com", "all_locations": "Boston, MA, USA; Cambridge, MA, USA", "long_description": "At XGenomes, we are building a technology comprising novel biochemistry, hardware and algorithms for sequencing DNA. Our product will be streamlined: there is zero library preparation; we sequence directly on unadulterated single molecules of DNA; DNA extraction will be integrated with sequencing; there is no bioinformatics bottleneck. The sequence we produce will be of unprecedented accuracy due to several layers of in-built redundancy including the sequencing both strands of the double-helix concurrently. The sequence we produce will be complete, encompassing: structural as well as single nucleotide variants; long-range haplotype phase; the repetitive \"dark matter\" of the genome. The cost of goods (consumables) of sequencing will be <$10, which will allow us to price our product at a level that will help grow the market while still achieving >90% margin. We will start by offering access as a service to high value customers, which be followed by a razor and blade model of selling instruments and consumables. ", "one_liner": "XGenomes is building the sequencing technology of the future. ", "team_size": 6, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1541806492, "tags": [ "Genomics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2019", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/xgenomes", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2019/xgenomes.json", "year_founded": 2017, "city": "Boston", "country": "US", "linkedin_url": "https://www.linkedin.com/company/xgenomes/", "x_url": "", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/xgenomes", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/4cca3d33a3a643c65629ce3164548e924340e550.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 288257, "full_name": "Kalim Mir", "title": "Founder/CEO", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/kalim-mir-b8037310/", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/0b51af9445e755a37e17624146bfc8245767778e.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 12657, "name": "Zergo", "slug": "zergo", "former_names": [ "SannTek Labs" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/ce8e4de67d63090a8cc6063dce90b126571c9bef.png", "website": "https://www.zergo.com/", "all_locations": "Waterloo, ON, Canada", "long_description": "", "one_liner": "We make a urine test that helps women get pregnant.", "team_size": 9, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1556763258, "tags": [ "Fertility Tech", "Hardware" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2019", "status": "Inactive", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "Canada", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/zergo", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2019/zergo.json", "year_founded": 2018, "city": "Waterloo", "country": "CA", "linkedin_url": "", "x_url": "", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/sanntek", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/ce8e4de67d63090a8cc6063dce90b126571c9bef.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 285627, "full_name": "Noah Debrincat", "title": "Founder", "founder_bio": "Previous founder of Zergo (S19)", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/noahdebrincat/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/772e2a30b4694269cb783d6bd9afc79dc11f1cae.jpg" }, { "user_id": 266703, "full_name": "Thomas Dunlop", "title": "Founder", "founder_bio": null, "is_active": true, "linkedin_url": "http://www.linkedin.com/in/thomas-dunlop-685533156", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/850637b234fc591b378de6e299170db2d169cdc2.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 13101, "name": "Segmed", "slug": "segmed", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/039d6d3be003fbf11b200cdc4996dd94be14fef9.png", "website": "https://segmed.ai", "all_locations": "San Francisco, CA, USA; Palo Alto, CA, USA; Remote", "long_description": "Segmed provides at-scale access to novel clinical data globally, offering millions of diagnostic-grade medical images to accelerate innovation and mature the evidence needs of life sciences and technology industry.\r\n‍\r\nOur solutions allow you to access a Real World Data (RWD) network to facilitate rapid discovery and investigational capability of imaging data, development of early disease detection & prediction models, improved patient recruitment and reduced operating burden to access therapeutic data ecosystem.", "one_liner": "Real-World Data for Health Innovation", "team_size": 32, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1583860791, "tags": [ "Health Tech", "Healthcare", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2020", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Fully Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/segmed", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2020/segmed.json", "year_founded": 2019, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/segmed-ai/?viewAsMember=true", "x_url": "https://twitter.com/Segmed_ai", "fb_url": null, "cb_url": null, "github_url": "https://github.com/segmed", "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/039d6d3be003fbf11b200cdc4996dd94be14fef9.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 331329, "full_name": "Martin Willemink", "title": "Founder", "founder_bio": "Co-founder and CEO at Segmed, Inc.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/martin-willemink/", "x_url": "https://twitter.com/MWillemink", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/e779a893f5773d146d793db7e2aac6cb4750c820.jpg" }, { "user_id": 332666, "full_name": "Jie Wu", "title": "Founder", "founder_bio": null, "is_active": true, "linkedin_url": "http://www.linkedin.com/in/jie-wu-467600b3", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/e60e420fd9cc339a56445f86a83f572bf3a9001b.jpg" } ], "jobs": [], "news": [ { "title": "Segmed Secures $10.4 Million Series A Funding, Led by iGan Partners and Advocate", "url": "https://www.segmed.ai/news/segmed-secures-10-4-million-series-a-funding-led-by-igan-partners-and-advocate-health", "date": "Sep 03, 2024" }, { "title": "YC and Alchemist-backed Segmed Raises $5.2M Funding Round and Launches Medical Real World Imaging Platform", "url": "https://www.prnewswire.com/news-releases/yc-and-alchemist-backed-segmed-raises-5-2m-funding-round-and-launches-medical-real-world-imaging-platform-301679062.html?tc=eml_cleartime", "date": "Jan 06, 2023" } ], "launches": [] }, { "id": 13220, "name": "Simple Strips", "slug": "simple-strips", "former_names": [ "Simple Strips (Lambert Labs Inc.)" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/7b48d64634d795b4a612106fa51ef61ddc04d681.png", "website": "https://simplestrips.com", "all_locations": "San Francisco, CA, USA", "long_description": "", "one_liner": "Low-cost blood glucose test strips scanned with a smartphone camera…", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1583979245, "tags": [ "Health Tech", "Diagnostics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2020", "status": "Inactive", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/simple-strips", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2020/simple-strips.json", "year_founded": null, "city": "San Francisco", "country": "US", "linkedin_url": "", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/7b48d64634d795b4a612106fa51ef61ddc04d681.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 257471, "full_name": "Sam Kanawati", "title": "Founder", "founder_bio": "", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/sam-kanawati", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/6c22f4335f10b5f3d0af64d8a1e007b246bed825.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 13406, "name": "Synapsica Healthcare", "slug": "synapsica-healthcare", "former_names": [ "Synapsica Technologies", "Synapsica Healthcare Inc" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/ae83920ac4eee163846bdc260d3911efe906c4d2.png", "website": "https://synapsica.com/", "all_locations": "Bengaluru, KA, India", "long_description": "", "one_liner": "AI-enabled automation of diagnostic radiology workflow and reporting.", "team_size": 30, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1583815450, "tags": [ "Marketplace", "SaaS", "B2B" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2020", "status": "Inactive", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "India", "South Asia", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/synapsica-healthcare", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2020/synapsica-healthcare.json", "year_founded": 2018, "city": "Bengaluru", "country": "IN", "linkedin_url": "https://www.linkedin.com/company/synapsica", "x_url": "https://twitter.com/SynapsicaAI", "fb_url": "https://www.facebook.com/SynapsicaAI", "cb_url": "https://www.crunchbase.com/organization/synapsica", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/ae83920ac4eee163846bdc260d3911efe906c4d2.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 417468, "full_name": "Cherian Dr", "title": "Founder", "founder_bio": null, "is_active": false, "linkedin_url": "https://www.linkedin.com/in/cherian-dr/", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/1c8b93a4750dafbd445c473fccb31b9a8d639f95.jpg" }, { "user_id": 418167, "full_name": "Gandharv Goyal", "title": "Founder", "founder_bio": "", "is_active": false, "linkedin_url": "https://www.linkedin.com/in/dr-gandharv/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/276d7b280e43570a513869e081ad8678c0910175.jpg" }, { "user_id": 343806, "full_name": "Kuldeep Singh Chauhan", "title": "Founder", "founder_bio": null, "is_active": false, "linkedin_url": "https://www.linkedin.com/in/kuldeepksc/", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/664d3572bae95119242f14df17e3f53e29f63ee2.jpg" }, { "user_id": 404981, "full_name": "Meenakshi Singh", "title": "Founder", "founder_bio": null, "is_active": false, "linkedin_url": "https://www.linkedin.com/in/meenakshi-singh-47903439/", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/036a7371338aa2f81052e721a5a6f2c3505691d3.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 13442, "name": "Isabl", "slug": "isabl", "former_names": [ "Isabl Technologies" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/2ee5c89ed172cfb330b2cb9f0f5e0f1a93886387.png", "website": "http://isabl.io", "all_locations": "New York City, NY, USA; New York, NY, USA; Remote", "long_description": "Isabl has developed software that can analyze the entire genome of cancer patients.\r\n\r\nToday, when people get cancer, they get a genetic test of their tumor that analyzes only a few possible mutations. With Isabl, you run the tumor through an Illumina sequencer and get the whole genome, then our software is able to analyze all the mutations.\r\n\r\nOur breakthrough technology provides unprecedented clarity into tumor biology to aid treatment planning. This opens up opportunities for precision diagnostics, disease surveillance and biomarker discovery.", "one_liner": "Cancer tests based on whole genome and transcriptome data.", "team_size": 5, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1652922754, "tags": [ "Biotech", "Diagnostics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2020", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Fully Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/isabl", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2020/isabl.json", "year_founded": 2020, "city": "New York City", "country": "US", "linkedin_url": "https://www.linkedin.com/company/isabl", "x_url": "https://twitter.com/isabl_io", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/2ee5c89ed172cfb330b2cb9f0f5e0f1a93886387.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 350037, "full_name": "Juan Medina", "title": "Founder", "founder_bio": "Co-Founder & CTO, Isabl Inc.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/jsmedmar/", "x_url": "https://twitter.com/jsmedmar", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/6d875b4784e240de51cc8be845c6f318f85cc372.jpg" }, { "user_id": 396330, "full_name": "Andrew Kung", "title": "Founder", "founder_bio": null, "is_active": true, "linkedin_url": "", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/db3b39473d026d2f126d3f1be3dad1c94be6942c.jpg" }, { "user_id": 401848, "full_name": "Elli Papaemmanuil", "title": "Founder", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/elli-papaemmanuil-0b8444b0", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/1cdce1afc995af3761b7bff7a29b24431c6c8e14.jpg" } ], "jobs": [], "news": [ { "title": "Isabl’s rapid whole-genome analysis opens the playbook for cancer treatment – TechCrunch", "url": "https://techcrunch.com/2022/05/18/isabls-rapid-whole-genome-analysis-opens-the-playbook-for-cancer-treatment/", "date": "May 18, 2022" } ], "launches": [] }, { "id": 13506, "name": "Nomic Bio", "slug": "nomic-bio", "former_names": [ "nplex biosciences" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/d3005075624cbc032b9abdd1525e6ec3201158f5.png", "website": "http://www.nomic.bio", "all_locations": "Montreal, QC, Canada", "long_description": "Nomic is doing for protein profiling, what Illumina did for DNA sequencing. Our core technology, the nELISA, is a next-gen immunoassay platform that transforms the ELISA into a high-throughput, high-content, and high-versatility tool. \r\n\r\nToday we developed the nELISA for high-throughput drug discovery scientists, enabling them profile 100s of proteins at 10x higher throughput and 10x lower cost compared to existing solutions. We're offering the nELISA through early access programs to HTS groups in top pharmas as well as pioneering biotechs in the space.\r\n\r\nOur goal is to create a ubiquitous technology that consolidates the broad range of legacy immunoassay toolkits that scientists use today with a single platform that can carry the science end-to-end, from discovery all the way to the clinic. \r\n\r\nWe're a team of engineers, biologists, and highly-skilled lab operators that are looking to grow quickly to keep up with customer demand but also to continue developing our core technology, scale our multiplexing/throughput, and build our software stack. We're hiring on a number of positions including engineering, software, biology, and ops. Come talk to us!", "one_liner": "Nomic is doing for proteins what Illumina has done for DNA", "team_size": 100, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1583898031, "tags": [ "Nanotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Winter 2020", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "Canada", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/nomic-bio", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2020/nomic-bio.json", "year_founded": 2017, "city": "Montreal", "country": "CA", "linkedin_url": "https://www.linkedin.com/company/nomicbio", "x_url": "https://twitter.com/nomicbio", "fb_url": null, "cb_url": null, "github_url": "https://github.com/nplexbio", "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/d3005075624cbc032b9abdd1525e6ec3201158f5.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": { "name": "Jared Friedman", "url": "https://www.ycombinator.com/people/jared-friedman" }, "founders": [ { "user_id": 348069, "full_name": "Milad Dagher", "title": "Founder", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/milad-dagher/", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/5e9b665b6c0e06ad38db091c0a3dcf258fdb1474.jpg" }, { "user_id": 284722, "full_name": "Jeff Munzar", "title": "Founder", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/jeffmunzar/", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/1a58ed2964c881b15c185864b39a05e0edf32114.jpg" } ], "jobs": [ { "id": 67109, "title": "Data Engineer", "url": "https://www.ycombinator.com/companies/nomic-bio/jobs/djdcWbI-data-engineer", "location": "Remote (United States) / Remote (US)", "type": "Full-time", "role": "Engineering", "role_type": "Full stack", "salary_range": "", "equity_range": "", "experience": "", "visa": "US citizen/visa only", "skills": [] }, { "id": 67110, "title": "Software Engineer (Jr to Sr Levels)", "url": "https://www.ycombinator.com/companies/nomic-bio/jobs/fQPrFFq-software-engineer-jr-to-sr-levels", "location": "Remote (United States) / Remote (US)", "type": "Full-time", "role": "Engineering", "role_type": "Full stack", "salary_range": "", "equity_range": "", "experience": "", "visa": "US citizen/visa only", "skills": [] }, { "id": 67111, "title": "R&D Lab Associate", "url": "https://www.ycombinator.com/companies/nomic-bio/jobs/tvcDSbW-r-d-lab-associate", "location": "Montreal", "type": "Full-time", "role": "Operations", "role_type": null, "salary_range": "", "equity_range": "", "experience": "", "visa": "US citizen/visa only", "skills": [] }, { "id": 67112, "title": "Data Associate", "url": "https://www.ycombinator.com/companies/nomic-bio/jobs/xPOgeWa-data-associate", "location": "Remote (United States) / Remote (US)", "type": "Full-time", "role": "Operations", "role_type": null, "salary_range": "", "equity_range": "", "experience": "", "visa": "US citizen/visa only", "skills": [] } ], "news": [ { "title": "Nomic collects $17M to advance its automated, high-throughput ELISA platform | FierceBiotech", "url": "https://www.fiercebiotech.com/medtech/nomic-collects-17m-to-advance-its-automated-high-throughput-elisa-platform", "date": "Dec 08, 2021" } ], "launches": [] }, { "id": 21737, "name": "LSK Technologies", "slug": "lsk-technologies", "former_names": [ "LSK Technologies Inc." ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/ca1d558dc356d3f2e123fbc02692cf8bafa1a131.png", "website": "https://www.lifesci-key.com/", "all_locations": "Toronto, ON, Canada", "long_description": "", "one_liner": "A diagnostic lab in a box", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1599762607, "tags": [ "Health Tech", "Diagnostics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2020", "status": "Acquired", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "Canada", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/lsk-technologies", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2020/lsk-technologies.json", "year_founded": 2020, "city": "Toronto", "country": "CA", "linkedin_url": "https://www.linkedin.com/company/lifesci-key/", "x_url": "https://twitter.com/LifeSciKey", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/ca1d558dc356d3f2e123fbc02692cf8bafa1a131.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 476229, "full_name": "Seray Cicek", "title": "Founder", "founder_bio": "Seray Cicek is a medical technology innovator and synthetic biology enthusiast. She holds a MSc in Pharmaceutical Sciences and BASc in Engineering Science (Biomedical) from the University of Toronto. She worked at Sanofi Pasteur, Vaccine Bulk Manufacturing Department. Her master's thesis focused on development and deployment of portable diagnostic devices for the detection of Zika virus from patient samples in Ecuador, Colombia and Brazil. Seray is the co-founder and CEO of LSK Technologies Inc.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/seray-%C3%A7i%C3%A7ek-803970a7/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/94f3bc6c06e9bb1a8b54b24d5e8c5bfaac860351.jpg" }, { "user_id": 492176, "full_name": "Livia Guo", "title": "Founder", "founder_bio": "This is Livia. I am currently a product manager working on digitizing biotherapeutics characterization for pharmaceutical companies. Prior to this role, I co-founded LSK Technologies, a diagnostic company with a vision to bring lab-quality disease testing outside of traditional laboratories. I am impact-driven with a passion for developing fast-scaling products.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/yuxiu-livia-guo-2a7806159/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/1df9f9c2e66c194f7160747fc1a28e9b0b64f25c.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 22080, "name": "Orange Health Labs", "slug": "orange-health-labs", "former_names": [ "Orange Health" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/3e07e4f8af878b1c646ca1ca04c557bb4e10c4a8.png", "website": "http://www.orangehealth.in", "all_locations": "Bengaluru, KA, India", "long_description": "Orange Health Labs is India’s leading on-demand diagnostics lab for urban consumers, offering 30-minute at-home sample collection and 6 hour reports across the top cities of India \r\n\r\nLaunched in January 2021, Orange Health Labs is amongst the most loved healthcare brands in India and is backed by some of the world’s leading investors like Accel, General Catalyst, Y Combinator, Bertelsmann India, Amazon, and others. ", "one_liner": "India's Fastest Diagnostics Service", "team_size": 1100, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1599762607, "tags": [ "Consumer Health Services", "Health Tech", "Healthcare", "Diagnostics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2020", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "India", "South Asia" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/orange-health-labs", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2020/orange-health-labs.json", "year_founded": 2020, "city": "Bengaluru", "country": "IN", "linkedin_url": "https://www.linkedin.com/company/orange-health/", "x_url": "https://twitter.com/OrangeHealth_", "fb_url": "https://play.google.com/store/apps/details?id=in.orangehealth.patient&hl=en_IN&gl=US&pli=1", "cb_url": "https://www.youtube.com/c/OrangeHealthLab", "github_url": "https://apps.apple.com/in/app/orange-health-labs-blood-test/id1534689588", "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/3e07e4f8af878b1c646ca1ca04c557bb4e10c4a8.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": { "name": "Brad Flora", "url": "https://www.ycombinator.com/people/brad-flora" }, "founders": [ { "user_id": 501755, "full_name": "Tarun Bhambra", "title": "Founder", "founder_bio": "Professional with over 10 years of experience across sectors as an operator, investor, consultant, product leader, and business head. Wants to make healthcare easier to access and patient-friendly. ", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/tarun-bhambra-a2ba104/", "x_url": "https://twitter.com/tarunbhambra", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/5b24a1937478a7507cef6533dd880a8d368494e6.jpg" }, { "user_id": 501499, "full_name": "Dhruv Gupta", "title": "Founder", "founder_bio": "Consumer tech entrepreneur with successful exits to Practo & HT Media. Product focused leader, built businesses in healthcare, commerce, and social networks, serving over 150M users every year. \nMore: www.dhruvg.com", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/dhruvgupta1/", "x_url": "https://twitter.com/dhruvg", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/c4b5d880659fade80c5f2cf2edc195fbc8887642.jpg" } ], "jobs": [], "news": [ { "title": " Amazon leads $12 Mn round in Orange Health", "url": "https://entrackr.com/snippets/amazon-smbhav-venture-leads-12-mn-round-in-orange-health-7779370", "date": "Dec 05, 2024" }, { "title": "Orange Health Labs raises $12 million from Amazon and others - The Economic Times", "url": "https://economictimes.indiatimes.com/tech/funding/orange-health-labs-raises-12-million-from-amazon-smbhav-others/articleshow/116013843.cms?from=mdr", "date": "Dec 05, 2024" }, { "title": "Healthtech Startup Orange Health Raises $25 Mn To Build New Labs", "url": "https://inc42.com/buzz/diagnostics-service-provider-orange-health%EF%BB%BF-raises-25-mn-dollar-to-build-new-labs/", "date": "Jun 01, 2022" } ], "launches": [] }, { "id": 22700, "name": "Moichor", "slug": "moichor", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/d684e5402c05c9cc17faca949952294cf3f7e3e0.png", "website": "https://moichor.com/", "all_locations": "San Francisco, CA, USA", "long_description": "Leveraging AI to provide veterinarians with more accurate and affordable diagnostics. \r\n\r\n\r\n", "one_liner": "AI Powered Animal Diagnostics", "team_size": 29, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1610738476, "tags": [ "Diagnostics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2021", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/moichor", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2021/moichor.json", "year_founded": 2019, "city": "San Francisco", "country": "US", "linkedin_url": "", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/d684e5402c05c9cc17faca949952294cf3f7e3e0.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 287583, "full_name": "Shevy Karbasi", "title": "Founder", "founder_bio": "", "is_active": false, "linkedin_url": "https://www.linkedin.com/in/shevy-karbasi-b3201b126/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/fc92768e3bd020d9975a94c5ce96385bf22bec14.jpg" }, { "user_id": 289272, "full_name": "Matthew Chen", "title": "Founder", "founder_bio": "Co-founder @ Moichor ", "is_active": false, "linkedin_url": "https://www.linkedin.com/in/mchen77/", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/d7c22eed1402f5dbdaa2f3f404ff97e9b9d4a5f2.jpg" }, { "user_id": 289361, "full_name": "Thanh Le", "title": "Founder", "founder_bio": "", "is_active": false, "linkedin_url": "https://www.linkedin.com/in/thanhxuanle/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/975397a2a50813d53040a54cb990ab1a9a8c3262.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 23146, "name": "Redcliffe Lifetech", "slug": "redcliffe-lifetech", "former_names": [ "Redcliffe Lifesciences" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/b9e3c4bc934297fbdde47eea1cf4c9de32e1a325.png", "website": "http://redcliffelabs.com", "all_locations": "Delhi, DL, India; Gurugram, HR, India; Noida, UP, India", "long_description": "Redcliffe Labs (a unit of Redcliffe Lifetech Inc) provides diagnostics with a comprehensive portfolio approach both with routine and specialised test menus with advanced testing labs all over India. Its digital first approach with on-demand 1-hour home collection and same day report is disrupting the way diagnostics is delivered today and thus is the fastest growing in India. \r\n\r\nRedcliffe Labs is providing 3500+ tests across its wide network of labs and collection centres. The company has served about millions of Indians and is processing more than 250K+ test parameters daily. The test portfolio is very wide including routine pathology tests, advanced genetic screening, research-based DNA tests in reproductive health, cancer and wellness/fitness. The easy to interpret smart reports provide key health check-points, which can help in diagnosing and treating both chronic and acute diseases on time. Redcliffe Labs has pioneered Drone technology adoption in the diagnostic sector by opening up the first commercial corridor from Uttarkashi to Dehradun. The company currently has 30+ labs and 700+ authorised collection centres in more than 120 cities across India. \r\n\r\nRedcliffe's vision is to provide world-class diagnostic services to people across the Indian sub-continent in an affordable manner.", "one_liner": "Redcliffe Labs is India's Largest Omni-channel Diagnostics platform ", "team_size": 3500, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1614617903, "tags": [ "Consumer Health Services", "Health Tech", "Digital Health", "Healthcare", "Diagnostics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2021", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "India", "South Asia" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/redcliffe-lifetech", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2021/redcliffe-lifetech.json", "year_founded": 2018, "city": "Delhi", "country": "IN", "linkedin_url": "https://www.linkedin.com/company/redcliffe-labs/", "x_url": "https://twitter.com/redcliffelab", "fb_url": "https://www.facebook.com/RedcliffeLabs/", "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/b9e3c4bc934297fbdde47eea1cf4c9de32e1a325.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": { "name": "Jared Friedman", "url": "https://www.ycombinator.com/people/jared-friedman" }, "founders": [ { "user_id": 597150, "full_name": "Dheeraj Jain", "title": "Founder", "founder_bio": "15 years of corp strategy and M&A, buyout global experience in Tech/Telecom/Health, 5 years of early stage investments, built successful women health D2C company (#1 fem hygiene brand in India), successful exits in Cancer Big Data, etc. Last 4 years only focused around improving health outcomes for Indian families using wide arrange new technologies, genomics, IVF treatments, etc. Met my co-founders at Redcliffe 8 years back and we realised this is our future. ", "is_active": true, "linkedin_url": "https://uk.linkedin.com/in/dheeraj-jain-4961352?challengeId=AQH_WYMY17jvTwAAAXS3lCwds9CeWzZFXmNa0rbrRI3rRN8kXGMEC0pvIfSICzj96-geUzT3XtlBn6n_bIUh6K0VOr4uUoBmBQ&submissionId=34695f9f-3036-3716-7fcf-56686be03875", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/1ef102c241fd86beae1005471caa5a874baa5f46.jpg" }, { "user_id": 685593, "full_name": "Aditya Kandoi", "title": "Founder", "founder_bio": "Aditya Kandoi was in consulting roles with Deloitte, Barclays, American Express in health and built health tech ventures in the past. He is passionate around women health and have depth in Indian Healthcare market with deep focus on Health-tech, his other strengths are around Digital Health operations.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/adityakandoi/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/0b56a3cc92d65612ab0a095edb4009166e8c02a1.jpg" } ], "jobs": [], "news": [ { "title": "How COVID-19 changed everything for diagnostics services startup Redcliffe Labs", "url": "https://yourstory.com/2022/06/diagnostics-services-startup-redcliffe-labs-healthcare-covid-19/amp", "date": "Jun 21, 2022" }, { "title": "India: Diagnostics platform Redcliffe Lifetech bags $61m from LeapFrog Investments", "url": "https://www.dealstreetasia.com/stories/redcliffe-raises-fresh-funds-291152?giftKey=4b7FE05E38i9", "date": "May 10, 2022" } ], "launches": [] }, { "id": 23511, "name": "Forcyte Biotechnologies", "slug": "forcyte-biotechnologies", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/f7b684971715c34dcf43972f00b40675ec273846.png", "website": "https://forcytebio.com/", "all_locations": "Los Angeles, CA, USA", "long_description": "In a nutshell: many diseases are caused by how much your cells squeeze (asthma, fibrosis, others). We discover drugs that control how much cells squeeze, with ease, to treat disease.\r\n\r\nWe use patented bioMEMS technology to turn cell strength (cells' ability to pull/ squeeze) into a quantifiable metric in drug discovery, to help find better drugs for mechanical diseases. \r\n\r\nWe screen 100,000s of drugs against numerous contractile human cell types to comprehensively map human mechanobiology (the \"contractome\") and identify promising drug development starting points to deliver novel medicines to treat mechanically-driven diseases including asthma, hypertension, preterm labor, fibrosis, and others.\r\n\r\n", "one_liner": "Discover drugs that control how much cells \"squeeze\" to treat disease", "team_size": 5, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1614755480, "tags": [ "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2021", "status": "Inactive", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/forcyte-biotechnologies", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2021/forcyte-biotechnologies.json", "year_founded": 2017, "city": "Los Angeles", "country": "US", "linkedin_url": "https://www.linkedin.com/company/forcyte-biotechnologies-inc", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/f7b684971715c34dcf43972f00b40675ec273846.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 589224, "full_name": "Ivan Pushkarsky", "title": "Founder", "founder_bio": "CEO and Co-founder of Forcyte which is based on my PhD work at UCLA with co-founder and PhD Advisor, Prof. Dino Di Carlo. Worked on tech since 2013, lead-authored multiple publications including Nature BME, and lead commercialization by winning SBIR grants, securing tech transfer and building early team.", "is_active": false, "linkedin_url": "https://www.linkedin.com/in/ivanpushkarsky/", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/54be667f96143a9b73b44a89f1064ea11262f5a6.jpg" }, { "user_id": 601870, "full_name": "Dino Di Carlo", "title": "Founder", "founder_bio": "Dino Di Carlo is a Professor, inventor, and entrepreneur with >50 issued patents. He is the Armond and Elena Hairapetian endowed chair in Engineering and Medicine at UCLA. His academic research has focused at the interface of micro & nanosystems, data science, and the ultimate limits of biology (single cells and molecules). Over the last 10 years, Dr. Di Carlo co-founded seven startup companies in life science research tools, diagnostics, medical device, and pharmaceutical industries. ", "is_active": false, "linkedin_url": "https://www.linkedin.com/in/dino-di-carlo/", "x_url": "https://twitter.com/dinodicarlo", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/9045d6c9a97af963cb749f531c62b7d9de5a5cb0.jpg" } ], "jobs": [], "news": [ { "title": "Mechano-therapeutics Discovery Startup Forcyte Bio Secures New Funding From Y Combinator & Others, Bringing Total to >$5.7 Million, to Develop Drug Pipeline | Business Wire", "url": "https://www.businesswire.com/news/home/20220601006160/en/Mechano-therapeutics-Discovery-Startup-Forcyte-Bio-Secures-New-Funding-From-Y-Combinator-Others-Bringing-Total-to-5.7-Million-to-Develop-Drug-Pipeline", "date": "Jun 02, 2022" } ], "launches": [] }, { "id": 23884, "name": "AOA Dx", "slug": "aoa-dx-inc", "former_names": [ "AOA Dx Inc." ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/664577ac1be84d91114d755fa8d02fcd2a69deb8.png", "website": "https://www.aoadx.com/", "all_locations": "Denver, CO, USA; Cambridge, MA, USA", "long_description": "AOA Dx is developing the next frontier in early-stage cancer detection for women through our pioneering work in glycolipids and proprietary biomarker technology. ", "one_liner": "Blood Test for Early Detection of Ovarian Cancer ", "team_size": 25, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1624286416, "tags": [ "Healthcare", "Diagnostics", "Women's Health" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": true, "app_answers": [ { "question": "Describe what your company does in 50 characters or less.\n", "answer": "Revolution in Ovarian Cancer" }, { "question": "How long have each of you been working on this? How much of that has been full-time? Please explain.\n", "answer": "We have been working on this project for 2 years. After the exit of last startup we were working on, we started a search for a new technology that would make a big impact on women's health. After evaluating over 20 technologies from different countries, we partnered with Prof. Uri Saragovi from McGill University. He discovered a novel way for early diagnosis of ovarian cancer. Oriana, the CEO has been full time working on this project since Sept 2019, with the other two co-founders joining full time in October 2020." }, { "question": "What is your company going to make? Please describe your product and what it does or will do.\n", "answer": "AOA seeks to revolutionize early-stage diagnosis of ovarian cancer by developing a non-invasive ovarian cancer liquid biopsy diagnostic test that will improve clinical practice by diagnosing ovarian cancer early. Early diagnosis will reduce patient mortality and deliver cost savings to payers. \r\n\r\nDue to non-specific symptoms, 80% of cases are diagnosed too late (stage III and IV) resulting in a five-year survival rate of only 28%. Current diagnostic methods are inadequate, lacking sensitivity and/or specificity, particularly during stages I and II. Women diagnosed early have a five-year survival rate of 90%. There is an urgent need to accurately diagnose women earlier to give them a fighting chance at survival. Our blood test is designed to do just that. " } ], "question_answers": null, "url": "https://www.ycombinator.com/companies/aoa-dx-inc", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2021/aoa-dx-inc.json", "year_founded": 2020, "city": "Denver", "country": "US", "linkedin_url": "https://www.linkedin.com/company/aoadx/", "x_url": "https://twitter.com/AOA_Dx", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/664577ac1be84d91114d755fa8d02fcd2a69deb8.png", "app_video_url": null, "dday_video_url": "https://bookface-images.s3.us-west-2.amazonaws.com/video_event/54/1630616753482-x1lcz72to1-79bed2a4848d96eb08ac351641b5df31/a3dcd32f6905b2d659cea8283d04698d.mp4?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIAQC4NIECABPQ2AHNW%2F20261020%2Fus-west-2%2Fs3%2Faws4_request&X-Amz-Date=20261020T022656Z&X-Amz-Expires=3600&X-Amz-SignedHeaders=host&X-Amz-Signature=6cd04d8f518cc8f710649249dd9cba8f3d62673098b08df51d63055d4ef67096", "company_photos": [ "https://bookface-images.s3.us-west-2.amazonaws.com/attachments/4be9033f667cf0de44de30e285de02c0c62f7c3d.png" ], "primary_partner": { "name": "Jared Friedman", "url": "https://www.ycombinator.com/people/jared-friedman" }, "founders": [ { "user_id": 706166, "full_name": "Oriana Papin-Zoghbi", "title": "Founder", "founder_bio": "CEO & Co-Founder AOA Dx Inc. Passionate about Women's Health. ", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/orianazh/", "x_url": "https://twitter.com/orianazh/", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/183d711521ab377ea1c7f07690be8ddb18d2a47f.jpg" }, { "user_id": 712028, "full_name": "Alex Fisher", "title": "Founder/COO", "founder_bio": "Chief Operating Officer & Co-Founder of AOA Dx. Passion about improving women's health. ", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/alexanderjfisher/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/b7615143270cf5248ff11eb559dae53f66f701dd.jpg" }, { "user_id": 712563, "full_name": "Anna Jeter", "title": "Founder", "founder_bio": "Chief Business Officer & Co-Founder", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/anna-milik-jeter-88036329/", "x_url": "https://twitter.com/anna_mj1", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/c73025c81ec05af5c8f5be78c2fad4072892e205.jpg" } ], "jobs": [], "news": [ { "title": "Exclusive: Liquid-biopsy startup closes $17M to fund ovarian cancer diagnostic test – Endpoints News", "url": "https://endpts.com/exclusive-liquid-biopsy-startup-closes-17m-series-b-to-fund-ovarian-cancer-diagnostic-test/", "date": "Oct 11, 2023" }, { "title": "AOA Dx Reaches Initial Validation of Novel Tumor Gangliosides as Diagnostic Markers for Early Detection of Ovarian Cancer – Femtech Insider", "url": "https://femtechinsider.com/aoa-dx-tumor-gangliosides-biomarker-ovarian-cancer/", "date": "Dec 08, 2022" }, { "title": "AOA Dx Closes $7 Million Funding Round To Bring The First Accurate Early Detection Test For Ovarian Cancer To Market", "url": "https://www.forbes.com/sites/marijabutkovic/2022/09/13/aoa-dx-closes-7-million-funding-round-to-bring-the-first-accurate-early-detection-test-for-ovarian-cancer-to-market/", "date": "Sep 13, 2022" }, { "title": "I Had a Baby While Preparing for Y Combinator.", "url": "https://www.businessinsider.com/y-combinator-startups-founder-stories-demo-day", "date": "Dec 02, 2021" }, { "title": "Y Combinator-backed AOA Raises $2.5 Million In Seed Funding To Develop First Non-Invasive Test Set To Revolutionize The Future Of Ovarian Cancer Diagnostics", "url": "https://www.forbes.com/sites/marijabutkovic/2021/06/28/y-combinator-backed-aoa-raises-25-million-in-seed-funding-to-develop-first-non-invasive-test-set-to-revolutionize-the-future-of-ovarian-cancer-diagnostics/?sh=12c652104f32", "date": "Jun 28, 2021" } ], "launches": [] }, { "id": 24368, "name": "Yemaachi Biotechnology", "slug": "yemaachi-biotechnology", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/0f20c99ceb3dc4f5663a9b43329248c249511272.png", "website": "https://yemaachi.com/", "all_locations": "Accra, Greater Accra Region, Ghana", "long_description": "Yemaachi Biotech is diversifying and expanding access to precision cancer diagnostics and therapeutics by collecting and sequencing samples from all across Africa, which is the most genetically diverse population on the planet. We then use this data to either optimize existing diagnostic tests, or help other companies discover new ones.\r\nWith our research activities based in Africa, we are able to leverage access to the most genetically diverse population on the planet to build a first-of-its-kind clinical and molecular knowledgebase on cancer among African people.", "one_liner": "Diversifying precision cancer diagnostics and treatments", "team_size": 16, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1627837386, "tags": [ "Biotech", "Diagnostics", "Therapeutics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "Ghana", "Africa" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/yemaachi-biotechnology", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2021/yemaachi-biotechnology.json", "year_founded": 2020, "city": "Accra", "country": "GH", "linkedin_url": "https://www.linkedin.com/company/yemaachi", "x_url": "https://twitter.com/YemaachiBio", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/0f20c99ceb3dc4f5663a9b43329248c249511272.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 706691, "full_name": "Yaw Bediako", "title": "Founder", "founder_bio": "With extensive expertise in cellular and molecular immunology, Yaw has a keen interest in immune function as relates to non-communicable diseases among African populations. Yaw is very active in efforts to promote the development of a sustainable research ecosystem across sub-Saharan Africa. He is one of 5 scientists selected in the inaugural round of the prestigious Crick Africa Network Fellowship, an affiliate member of the African Academy of Sciences and a fellow of the Ghana Young Academy.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/yaw-bediako-ph-d-8082a152/", "x_url": "https://twitter.com/YawBediako_", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/5be9e93e453309667e64245e5edc0d60fc836643.jpg" }, { "user_id": 726666, "full_name": "Yaw Attua-Afari", "title": "Founder", "founder_bio": "Finance and Investment professional with experience in investment banking and private equity (covering various sectors) in the US and Africa. Keen interest in high impact businesses. Co-founder and CFO of Yemaachi Biotech. ", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/yaw-a-930b8312/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/b211c2853f2933aa810dd8242916b47a1a1c32d7.jpg" }, { "user_id": 736729, "full_name": "David Hutchful", "title": "Founder", "founder_bio": "I am passionate about designing and building tech solutions that are informed by a nuanced understanding of the socio-economic and cultural contexts of the problems. I've worked in the private (Microsoft Research) and non-profit (Grameen Foundation) sectors and built companies that use technology to improve peoples' lives.\n\nWhen I am not hacking ideas or technology, I love to read, travel and experience different cultures. I am always available to play or watch football.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/dhutchful/", "x_url": "https://twitter.com/dhutchful", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/1e6eb2ad499821689baeef5203525af5b70aac01.jpg" }, { "user_id": 736928, "full_name": "Joyce Ngoi", "title": "Founder", "founder_bio": "", "is_active": true, "linkedin_url": "", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/6b43d99f4fd595ba7563905aea4bf31892e3288d.jpg" } ], "jobs": [], "news": [ { "title": "Ghanaian Startup Yemaachi secures $3M in Seed Funding", "url": "https://techbuild.africa/ghanaian-startup-yemaachi-3m-in-seed-funding/", "date": "Mar 22, 2022" }, { "title": "Yemaachi, Africa’s Cancer Research Company, Raises Seed Round To Diversify Genomic Datasets & Advance Precision Oncology Globally | Business Wire", "url": "https://www.businesswire.com/news/home/20220321005271/en/Yemaachi-Africa%E2%80%99s-Cancer-Research-Company-Raises-Seed-Round-To-Diversify-Genomic-Datasets-Advance-Precision-Oncology-Globally", "date": "Mar 21, 2022" }, { "title": "Yeemachi Biotechnology Selected For Y Combinator S21 Batch - Tech Nova", "url": "https://technovagh.com/yeemachi-biotechnology-selected-for-y-combinator-s21-batch/", "date": "Aug 09, 2021" }, { "title": "Quest for Research Freedom Fuels African Biotech Boom | The Scientist Magazine®", "url": "https://www.the-scientist.com/bio-business/quest-for-research-freedom-fuels-african-biotech-boom-68878", "date": "Aug 01, 2021" } ], "launches": [] }, { "id": 24445, "name": "Digistain", "slug": "digistain", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/ee811a143d9362213ecd8df87fca7780ce1945b8.png", "website": "https://digistain.co.uk/", "all_locations": "London, England, United Kingdom", "long_description": "In the global fight against breast cancer, Digistain stands at the forefront, offering a beacon of hope to millions. Our journey began at Imperial College London, where ground-breaking research gave birth to a technology poised to revolutionize breast cancer diagnostics.\r\n\r\nThe Challenge: Every year, breast cancer affects 2.3 million individuals globally. Post-surgery, 60% of patients are advised to undergo genomic testing, an expensive and time-consuming process monopolized by a single lab in the U.S., costing around $4,000 and taking nearly two months. Consequently, only 5% undergo this vital testing. The rest, unable to access this crucial diagnostic step, often resort to chemotherapy—a treatment that, in one in four cases, is more harmful than the cancer itself.\r\n\r\nOur Solution: Digistain addresses this critical gap. Our technology transforms the current diagnostic process by enabling hospitals to analyze patient samples in-house using existing equipment, supplemented with our innovative technology. This approach offers near-instantaneous decision-making data, a stark contrast to the existing month-long waits. Central to our technology is a proprietary algorithm that identifies a unique spectral fingerprint of the tumour in the infrared spectrum, providing a personalized risk score. This score guides oncologists in selecting the most effective, individualized treatment plans, potentially reducing unnecessary chemotherapy and its harmful side effects.\r\n\r\nImpact and Potential: Our solution not only challenges the status quo in technology but also in accessibility. In a landmark government-commissioned study, Digistain demonstrated clinical evidence on par with the market leader, but at a fraction of the cost and time. Already making waves in clinical practice globally, with insurance reimbursement at leading cancer centers, our technology represents a paradigm shift in cancer care.\r\n\r\nRecognized by the Institute of Physics, the Royal Society, and Imperial College for our innovative contributions, and supported by entities like the NHS, Y Combinator, and the European Investment Bank, Digistain is more than a company—it’s a movement towards equitable, effective cancer treatment. With the potential to democratize access to life-saving diagnostics, Digistain is not just envisioning a better future for cancer patients; we are actively creating it.\r\n ", "one_liner": "Pioneering Breast Cancer Diagnostics for a Healthier Tomorrow", "team_size": 40, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1624636740, "tags": [ "Medical Devices" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United Kingdom", "Europe" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/digistain", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2021/digistain.json", "year_founded": 2019, "city": "London", "country": "GB", "linkedin_url": "https://uk.linkedin.com/company/digistain", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/ee811a143d9362213ecd8df87fca7780ce1945b8.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 410138, "full_name": "Hemmel Amrania", "title": "Founder", "founder_bio": "Hemmel Amrania Ph.D, CEO has previously scaled several 7 figure businesses both in therapeutics and diagnostics. As a doctoral researcher he was awarded the Outstanding Research Prize at Imperial College London. He has also won several UK business awards including the Innovation & Entrepreneurship Challenge Imperial College and the Climate KIC Competition held by the Mayor of London. For Digistain he spear-headed the research out of the lab all the way through to clinical trials.\n", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/hemmel-amrania/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/d9f3ec4a24a122d7cb94bf65ef53a3cd13478559.jpg" }, { "user_id": 739775, "full_name": "Chris Phillips", "title": "Founder", "founder_bio": "Chris is an Imperial College Physics Professor, researching into photovoltaics, and biomedical imaging. He's spent the last few years, with Hemmel Amrania, developing the Digistain cancer diagnosis technology with Imperial medics.\n\nHe has won a number of prizes and has explained his research on invisibility caused by quantum optical effects to comedy legend Cleese on TV. He once rowed 500 miles non-stop from London to Paris. See https://en.wikipedia.org/wiki/Chris_Phillips_(professor)", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/chris-phillips-a650151b/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/484ecb78dede011ebb62e44c047cf5943c04f728.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 24450, "name": "Astek Diagnostics", "slug": "astek-diagnostics-inc", "former_names": [ "Astek Diagnostics LLC" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/0cc751641f3edca70063a728f7fc978cc2df8169.png", "website": "http://astekdx.com", "all_locations": "Baltimore, MD, USA", "long_description": "Astek Diagnostics is building a platform (Eugris) that guides physicians in prescribing appropriate antibiotics for patients with bacterial sepsis in one hour. It is done by detecting the oxygen consumption of the bacteria", "one_liner": "One-hour antibiotic sensitivity testing", "team_size": 5, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1625157553, "tags": [ "Microfluidics", "Medical Devices" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/astek-diagnostics-inc", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2021/astek-diagnostics-inc.json", "year_founded": 2020, "city": "Baltimore", "country": "US", "linkedin_url": "", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/0cc751641f3edca70063a728f7fc978cc2df8169.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 698468, "full_name": "Mustafa Al-Adhami", "title": "Founder", "founder_bio": "Mustafa Al-Adhami Ph.D., CEO, Astek Diagnostics. He has long experience in customer discovery and diagnostics. He envisioned the technology behind Eugris while completing his PhD. As a doctoral student, he won the national Three Minute Thesis (3mt) competition, Baylor Business Plan, elevator pitch competition, and VentureWell’s BMEidea competition. Mustafa has raised over $5M for Astek to date to revolutionize antibiotic prescription. ", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/maladhami/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/c3d6e397e9c04bcafd4a4570763f1a8fd437a1e9.jpg" } ], "jobs": [], "news": [ { "title": "Y Combinator alum Astek wants to revolutionize antibiotics - Technical.ly", "url": "https://technical.ly/2022/01/18/astek-diagnostics-antibiotics-y-combinator/", "date": "Jan 18, 2022" } ], "launches": [] }, { "id": 24622, "name": "Caire Health", "slug": "caire-health", "former_names": [ "CAIRE" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/97361364dc226255ea7672c56e73b4967ef83a2e.png", "website": "http://cairehealthinc.com", "all_locations": "FL, USA", "long_description": "We believe that no emergency should have to wait. To make this a reality we build AI that instantly reads medical scans and enables critical care teams to make diagnoses better than radiologists. This saves lives by getting emergencies to treatment immediately and by discharging non-emergent patients quickly so the next emergency doesn’t have to wait either.\r\n", "one_liner": "Semi-Autonomous Diagnostics for Emergent Care", "team_size": 3, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1628310950, "tags": [ "Medical Devices", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/caire-health", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2021/caire-health.json", "year_founded": 2021, "city": null, "country": "US", "linkedin_url": "https://www.linkedin.com/company/caire-health/about/", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/97361364dc226255ea7672c56e73b4967ef83a2e.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 256980, "full_name": "Anmol Warman", "title": "Founder", "founder_bio": "", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/anmol-warman-139820160/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/89333bcf97c52ed50b7a78c616ea6ec767b07a0d.jpg" }, { "user_id": 253683, "full_name": "Pranav Warman", "title": "Founder", "founder_bio": "", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/pranavwarman/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/33242076eb03baaf3d3921c554e66d394d8e270e.jpg" }, { "user_id": 470998, "full_name": "Roshan Warman", "title": "Founder", "founder_bio": "", "is_active": true, "linkedin_url": "", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/a33f7a088cae02bec2152730b13957ed646e56b7.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 24820, "name": "Medium Biosciences", "slug": "medium-biosciences", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/0f30f00dbe44cde67296a43e445c0bb0dc14f9b5.png", "website": "http://medium.bio", "all_locations": "Austin, TX, USA", "long_description": "We turn advances in AI and protein design into experimentally validated molecular tools, partnering with research teams and diagnostic developers to deliver high-performance affinity reagents in weeks, not months.\r\n", "one_liner": "AI-designed Affinity Reagents", "team_size": 6, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1630004252, "tags": [ "Machine Learning", "Biotech", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/medium-biosciences", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2021/medium-biosciences.json", "year_founded": 2021, "city": "Austin", "country": "US", "linkedin_url": "https://www.linkedin.com/company/medium-biosciences/", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/0f30f00dbe44cde67296a43e445c0bb0dc14f9b5.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 130219, "full_name": "Mohamed Hassan Kane", "title": "Founder", "founder_bio": "Studied CS & AI at MIT. Published 8 papers across LLMs, computer vision, and protein design. Now: AI & protein design → reagents", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/mohamed-hassan-kane-4b50328a?trk=nav_responsive_tab_profile", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/bd95d845bbd3e9733eb11660b79aa664d41113cb.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 24840, "name": "VedaBio", "slug": "vedabio", "former_names": [ "LabSimply", "Labsimply", "Inc." ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/f36960de43508b6e6c447cab7a3cfcb402d9411f.png", "website": "https://www.vedabio.com", "all_locations": "San Diego, CA, USA; Urbana, IL, USA", "long_description": "Syndromic testing powered by engineered CRISPR enzymes. Get comprehensive results in every doctor visit. More at www.vedabio.com", "one_liner": "CRISPR powered Diagnostics with results in minutes.", "team_size": 30, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1626385432, "tags": [ "Hard Tech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/vedabio", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2021/vedabio.json", "year_founded": 2021, "city": "San Diego", "country": "US", "linkedin_url": "https://www.linkedin.com/company/labsimply/", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/f36960de43508b6e6c447cab7a3cfcb402d9411f.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": { "name": "Jared Friedman", "url": "https://www.ycombinator.com/people/jared-friedman" }, "founders": [ { "user_id": 428536, "full_name": "Anurup Ganguli", "title": "Founder", "founder_bio": "Passionate about leveraging technology to solve real-world problems and build solutions that scale.", "is_active": false, "linkedin_url": "https://www.linkedin.com/in/anurup-ganguli-phd-24a22419/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/6ad6500e6177c155c28fec37c2f3050d11813d3e.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 25110, "name": "Spot Health", "slug": "spot-health", "former_names": [ "Spot" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/0ffec8c45537c093646d5b42339f3c6147d96cd7.png", "website": "https://spotdx.com", "all_locations": "Cincinnati, OH, USA", "long_description": "Spot is building the infrastructure to support the future of at-home diagnostics. Our fully white-labeled platform helps brands offer lab-analyzed diagnostic tests using at-home collection kits. Companies simply order tests via our API, and we handle the rest—the collection kits, the logistics, physician authorization, and the lab integrations.", "one_liner": "At-home diagnostics as a service", "team_size": 9, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1647881296, "tags": [ "Telehealth", "Healthcare", "Diagnostics" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Winter 2022", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/spot-health", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2022/spot-health.json", "year_founded": 2021, "city": "Cincinnati", "country": "US", "linkedin_url": "https://www.linkedin.com/company/spotkits/", "x_url": "", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/spot-health", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/0ffec8c45537c093646d5b42339f3c6147d96cd7.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 285088, "full_name": "Andrew Jajack", "title": "Founder", "founder_bio": "", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/ajajack/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/3bd2abd12c9e0a1a5cf8a753482e8530b8db4068.jpg" } ], "jobs": [ { "id": 62719, "title": "Growth Operations", "url": "https://www.ycombinator.com/companies/spot-health/jobs/iC9fBXs-growth-operations", "location": "US / Remote (US)", "type": "Full-time", "role": "Operations", "role_type": null, "salary_range": "$50K - $75K", "equity_range": "", "experience": "3+ years", "visa": "US citizen/visa only", "skills": [] }, { "id": 62720, "title": "Operations Associate", "url": "https://www.ycombinator.com/companies/spot-health/jobs/fXuPeXx-operations-associate", "location": "Cincinnati, OH, US", "type": "Internship", "role": "Operations", "role_type": null, "salary_range": "", "equity_range": "", "experience": null, "visa": "US citizen/visa only", "skills": [] }, { "id": 67465, "title": "Founding Engineer", "url": "https://www.ycombinator.com/companies/spot-health/jobs/dy9ZiK1-founding-engineer", "location": "Remote (US)", "type": "Full-time", "role": "Engineering", "role_type": "Full stack", "salary_range": "$100K - $200K", "equity_range": "", "experience": "3+ years", "visa": "US citizen/visa only", "skills": [ "Amazon Web Services (AWS)", "Django", "PostgreSQL", "React" ] } ], "news": [], "launches": [] }, { "id": 25285, "name": "Scout", "slug": "scout-2", "former_names": [ "Uh-Oh Labs", "Scout (formerly Uh-Oh Labs)" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/aef2a50967bbb0e1e0f4bc9ebba4727befed3822.png", "website": "http://scouthealth.com", "all_locations": "San Francisco, CA, USA", "long_description": "Digital health holds a lot of potential but is ignoring a growing problem: diagnostic testing. Without this data, providers and organizations will be limited in the services they can provide patients at home.\r\n\r\nScout has developed a platform - Hub, test kits, and app - that delivers health testing at home with 10x lower development cost and 3x lower per-test price. Our patented tech also meets performance requirements for medical diagnoses and integrates with the current healthcare tech stack. Scout’s technology is poised to disrupt the outdated $33Bn diagnostic market by democratizing testing while dramatically improving the patient experience.\r\n\r\nScout has received $16M in non-dilutive funding from the NIH and other organizations to fully de-risk our platform, and our pipeline includes a diverse test menu for primary care (e.g. respiratory and sexual health), wellness (e.g. gut health), and chronic conditions (e.g. certain cancers). We have already received FDA authorization for our platform in clinical settings and are planning to launch our flagship Scout Hub in 2024.", "one_liner": "The smart testing platform that unlocks digital health at home.", "team_size": 12, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1645122247, "tags": [ "Consumer Health Services", "COVID-19", "Health Tech", "Diagnostics", "Consumer Products" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2022", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/scout-2", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2022/scout-2.json", "year_founded": 2018, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/uh-oh-labs/", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/aef2a50967bbb0e1e0f4bc9ebba4727befed3822.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 763781, "full_name": "Alex Jiao", "title": "Founder/CEO", "founder_bio": "Bioengineering PhD trained in stem cell biology & tissue engineering (cardiac & skeletal muscle) and now in molecular diagnostics. Worked in biopharma therapy development (small molecule, biologics, gene therapy). Started and Silene Biotech and now working at Scout (formerly Uh-Oh Labs) as President and Chief Business Officer. ", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/alexjiao/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/dbe354430cf499ef3fb35acbed717cc31bb4f95f.jpg" }, { "user_id": 764147, "full_name": "Cameron Ball", "title": "Founder", "founder_bio": "Cam is an accomplished biomedical engineer and entrepreneur. Before starting Uh-Oh Labs, Cameron worked at Sandia National Laboratories. Cameron is an expert in molecular diagnostics, microfluidics, materials science, and drug delivery. With 12 years of experience as a biomedical engineer, he brings a command of cross-functional engineering skills and fundamental science knowledge to bear on complex problems in biological systems.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/cameronsball/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/b0a66b6aaa8a3c5ce5f95ac80f1b7321054022ac.jpg" } ], "jobs": [], "news": [ { "title": "Democratized diagnostics: Uh-Oh Labs develops tech for accurate COVID home tests and beyond - GeekWire", "url": "https://www.geekwire.com/2022/democratized-diagnostics-uh-oh-labs-develops-tech-for-accurate-covid-home-tests-and-beyond/", "date": "Feb 17, 2022" } ], "launches": [] }, { "id": 25327, "name": "Starling", "slug": "starling", "former_names": [ "Starling Medical" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/cdc25280245ff89ae883c07e3aa55cf751c7c285.png", "website": "https://starlingmedical.com/", "all_locations": "Houston, TX, USA", "long_description": "Starling is building a urine diagnostic remote patient monitoring platform that seamlessly integrates into anyone's bathroom routine. By detecting early changes in a patient's urine using our toilet indwelling mass spectroscopy device, our platform is aiming to prevent hospitalizations from numerous conditions like recurrent UTIs, BPH exacerbations, or diabetes. We do this while creating significant new annual revenues for our clinician partners from remote patient monitoring reimbursements without requiring any significant changes in a staff's day to day schedule. ", "one_liner": "AI enabling digital urine diagnostics in the home", "team_size": 5, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1644279781, "tags": [ "Machine Learning", "Medical Devices", "Digital Health" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2022", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/starling", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2022/starling.json", "year_founded": 2019, "city": "Houston", "country": "US", "linkedin_url": "https://www.linkedin.com/company/starling-medical", "x_url": "https://twitter.com/StarlingMedical", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/starling-medical", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/cdc25280245ff89ae883c07e3aa55cf751c7c285.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 739344, "full_name": "Drew Hendricks", "title": "Founder", "founder_bio": "I am a health-tech entrepreneur with a special interest in all things urine and diagnostic. My background in medicine and medical device design gives me a unique point of view while identifying major gaps in healthcare through regular patient interaction. ", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/drew-hendricks/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/65775c5df4a3bb77487be7d624a6c4646f77d8eb.jpg" }, { "user_id": 740020, "full_name": "Hannah McKenney", "title": "Founder", "founder_bio": "My experience within both the hospital and industry setting has developed my interest in emphasising the user-centered and human factors design of medical technologies to ensure accessibility and usability in all areas around the world. My skills are broadly in problem definition, upstream product development, and implementation of medical technologies (device and digital health) in the clinical setting. I am focused on ensuring Starling prioritises the user experience throughout our growth.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/hmck96/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/59ec4cee30bd011012518f725abac51cd46d1d17.jpg" } ], "jobs": [], "news": [ { "title": "American Telemedicine Association announced telehealth innovators challenge vict", "url": "https://www.fiercehealthcare.com/telehealth/american-telemedicine-association-announced-12-telehealth-innovators-challenge-finalists", "date": "Mar 15, 2023" }, { "title": "Starling Medical’s new urine-testing device turns your toilet into a health tracker • TechCrunch", "url": "https://techcrunch.com/2023/01/27/starling-medical-urine-health/", "date": "Jan 27, 2023" }, { "title": "In conversation with Alex Arevalos and Sylvie Kalikoff, Starling Medical - Praxis Spinal Cord Institute", "url": "https://praxisinstitute.org/in-conversation-with-alex-arevalos-and-sylvie-kalikoff-starling-medical/", "date": "Feb 11, 2021" } ], "launches": [] }, { "id": 26751, "name": "Signatur Biosciences", "slug": "signatur-biosciences", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/3bad55d9462a3252670af9b86ed4d9abc2a388f4.png", "website": "https://www.signatur.bio/", "all_locations": "London, England, United Kingdom", "long_description": "We make precision diagnostics more accessible, starting with breast cancer prognosis. Current tests that guide the use of therapy are really slow and expensive because they need to be run in complex centralized facilities. Our tests are designed to be easily run by local hospital labs, reducing turnaround time from over three weeks to a few days and for a fraction of the price.", "one_liner": "Simple tests for complex diseases.", "team_size": 5, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1657207796, "tags": [ "Biotech", "Healthcare", "Diagnostics" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Summer 2022", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United Kingdom", "Europe", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/signatur-biosciences", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2022/signatur-biosciences.json", "year_founded": 2022, "city": "London", "country": "GB", "linkedin_url": "https://www.linkedin.com/company/signatur-bio/", "x_url": "https://twitter.com/SignaturBio", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/3bad55d9462a3252670af9b86ed4d9abc2a388f4.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 930500, "full_name": "John Goertz", "title": "Founder", "founder_bio": "Co-founder, CSO, and PCRchitect at Signatur Biosciences. I teach machine learning to molecules to expand the range of diseases we can diagnose with PCR. NIH F32 Postdoctoral Fellow in the the Stevens Group at Imperial College London; PhD Bioengineering from University of Maryland, College Park; BSc Physics and Cell & Molecular Biology from Seattle University. When I’m not programming DNA, I’m cooking, running, or doing martial arts (Danzan-Ryu Japanese Jujitsu).", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/johngoertz/", "x_url": "https://www.twitter.com/BioGoertz", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/6cb661d1fc1b8e8930f1a1224ac10aa02075fbad.jpg" }, { "user_id": 924455, "full_name": "Celestin de Wergifosse", "title": "Founder", "founder_bio": "Co-founder and CEO of Signatur Biosciences. Startups since the age of 14. First patent at 15. WIPO Best Young Inventor 2010. Twice TEDx speaker. Co-founded Young Change Maker, a social startup that highlights inspiring individuals. Co-founded and sold a company called Sauna en Bois. Bio-engineering from Imperial College London. When I don't work, I race motorcycles, climb or ski. My life-long goal is to develop biotech companies that address global issues.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/celestin-de-wergifosse-41b9823b/", "x_url": "https://twitter.com/CelestindeWer", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/21175fb3644f2f8fd7550c0996f6527758d38389.jpg" } ], "jobs": [ { "id": 116867, "title": "Lab Officer (Liège, Belgium)", "url": "https://www.ycombinator.com/companies/signatur-biosciences/jobs/RCUUWfh-lab-officer-liege-belgium", "location": "Liège, Belgium", "type": "Full-time", "role": "Science", "role_type": "Laboratory", "salary_range": "", "equity_range": "", "experience": "Any (new grads ok)", "visa": "US citizenship/visa not required", "skills": [] } ], "news": [ { "title": "A simple PCR to predict the effectiveness of chemotherapy (translated)", "url": "https://www.lecho.be/entreprises/pharma-biotechnologie/un-simple-pcr-pour-predire-l-efficacite-d-une-chimio/10497271.html", "date": "Oct 05, 2023" } ], "launches": [ { "id": 64421, "title": "🧪 Signatur Biosciences diagnoses anything with a simple PCR test.", "tagline": "We expand PCR testing to a whole new range of diseases!", "body": "**tl;dr:** Signatur Biosciences is a B2B molecular diagnostics design company. Our technology expands PCR testing to a whole new range of conditions. We design smart PCR kits that can detect complex diseases as easily as a COVID test, using standard qPCR machines. Our tests seamlessly integrate into existing clinical workflows and ubiquitous laboratory instruments, empowering us to become _the_ enabling technology platform for a $20B industry.\n\n👋 Hey everyone! We’re Celestin and John. We are determined to transform the state of medical diagnostics. We set out to find a solution that delivers state-of-the art diagnosis on ubiquitous instrumentation to put cutting-edge healthcare within the reach of everyone, everywhere.\n\n### **The Problem.**\n\nRight now, PCR testing is limited to simple diseases. Covid is a good example. You take a sample from a patient and look for one biomarker. If the biomarker is there, the patient has the disease; no biomarker, no disease. Simple.\n\nBut most conditions aren't that simple. There’s a $20B industry using _patterns_ of multiple biomarkers that diagnose complex diseases, but to deploy their tests they’re relying on legacy technologies that are too slow and expensive to really help people, limiting their market reach.\n\n### **🧬 Signatur Biosciences’s solution.**\n\nOur platform expands PCR testing to a whole new range of conditions, beyond just infectious disease to include everything from chronic diseases, treatment selection, and disease monitoring.\n\nWe have re-engineered the molecular architecture of the polymerase chain reaction, empowering it to process the information from multiple biomarkers simultaneously. We combine the power of gene signature diagnosis with the **_ease and familiarity of a single PCR reaction._**\n\nEvery biomedical lab in the planet is equipped with PCR machines. This was true before the pandemic. But as a response to the pandemic, the PCR testing capacity in the US has increased by 5500% (3000% in the UK). We are giving those machines something new to do.\n\n### **🚀 How can Signatur Biosciences help me?**\n\nWe are partnering with companies to design our platform around their biomarker panels, offering broader market reach bringing such tests to more patients.\n\nIn parallel, we are building our own assay portfolio. We are developing our own internal pipeline of tests to tackle diseases that can only be interrogated by our technology.\n\n### **How you can help.**\n\nWe are looking for introductions to companies in the molecular diagnostics space. This could be companies developing portable hardware. Specifically developing genomic testing, or assays based on gene expression analysis.", "url": "https://www.ycombinator.com/launches/Gl3-signatur-biosciences-diagnoses-anything-with-a-simple-pcr-test", "votes": 20, "created_at": "2022-07-07T15:51:11.366Z" } ] }, { "id": 27828, "name": "Scanbase", "slug": "scanbase", "former_names": [ "Scanbase", "Inc." ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/c9177f461ffabba1796fab772ec9f376ad91bf4e.png", "website": "https://www.scanbase.com", "all_locations": "Los Angeles, CA, USA", "long_description": "Scanbase makes it easy for medical companies to convert photos of rapid diagnostic tests into results. We do this by providing a simple API that any medical company can access.\r\n", "one_liner": "The API for Diagnostic Test Analysis (COVID-19, FLU, RSV, STD,…", "team_size": 10, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1670991822, "tags": [ "Machine Learning", "Computer Vision", "Health Tech", "Telemedicine", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2023", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/scanbase", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2023/scanbase.json", "year_founded": 2022, "city": "Los Angeles", "country": "US", "linkedin_url": "https://www.linkedin.com/company/scanbases/", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/c9177f461ffabba1796fab772ec9f376ad91bf4e.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": { "name": "Tom Blomfield", "url": "https://www.ycombinator.com/people/tom-blomfield" }, "founders": [ { "user_id": 1162081, "full_name": "Jeffrey Lange", "title": "Founder", "founder_bio": "Jeffrey is currently the CEO of Scanbase, a seed stage diagnostic scanning API used by at-home test manufacturers. He is a graduate of the Rhode Island School of Design.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/langejeff/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/88486d8d8917eb91776d16c6f3b5540f5e751853.jpg" }, { "user_id": 1150701, "full_name": "Steve Roger", "title": "Founder", "founder_bio": "CTO of Scanbase with 10+ years building enterprise level APIs, and products. Steve holds a degree in CS from UC Berkeley. Ex-LinkedIn.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/steveroger/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/2ef49967996d38086a75f694673b3814fe366c7b.jpg" } ], "jobs": [], "news": [ { "title": "Y Combinator’s Most Recent Winter 2023 Batch Shows A Shift To AI, DevTools And B2B ", "url": "https://news.crunchbase.com/venture/y-combinator-winter-2023-shift-ai-devtools-b2b/", "date": "Apr 12, 2023" }, { "title": "Our favorite startups from YC’s Winter 2023 Demo Day — Part 2 | TechCrunch", "url": "https://techcrunch.com/2023/04/06/y-combinator-demo-day-2023-favorites-part-two/", "date": "Apr 06, 2023" } ], "launches": [ { "id": 68414, "title": "Scanbase API - Converting Diagnostic Tests to Results, Next Steps, and Treatment", "tagline": "COVID-19, Flu, Pregnancy, RSV, STD/STI, HIV, CKD, UTI, and many more...", "body": "![uploaded image](/media/?type=post&id=68414&key=user_uploads/1162081/724cd23c-f4df-4100-954e-379c4f248340)\n\n![uploaded image](/media/?type=post&id=68414&key=user_uploads/1162081/047c2be5-f90d-4a0b-acc6-693a32527879)\n\n![uploaded image](/media/?type=post&id=68414&key=user_uploads/1162081/d6a6fc05-b35f-4382-8d04-5a1c04c5bec0)\n\n[Book a demo](https://www.scanbase.com/schedule-a-demo) and learn how Scanbase can enhance your diagnostic program.\n\n![uploaded image](/media/?type=post&id=68414&key=user_uploads/1162081/9151ad3b-aee8-469f-85a8-865f70e98b45)\n\nWatch a demo of a Scanbase’s algorithm interpreting a **low positive** test!\n\n![uploaded image](/media/?type=post&id=68414&key=user_uploads/1162081/bb4bb5c4-0806-4417-a3e9-a05347115195)\n\n![uploaded image](/media/?type=post&id=68414&key=user_uploads/1162081/c31413ed-9102-4eb6-acfd-f4016a843ab4)\n\n![uploaded image](/media/?type=post&id=68414&key=user_uploads/1162081/b9e1ac86-a480-48f7-9663-57c6dc724723)\n\nInterested in digitizing your diagnostic tests and don’t have an app? Reach out to us at [info@scanbase.com](mailto:info@scanbase.com) to learn how we’re helping diagnostics companies digitize from the ground up.\n\n![uploaded image](/media/?type=post&id=68414&key=user_uploads/1162081/4378e1d7-15cd-4dfa-88af-66f0c64babeb)\n\n![uploaded image](/media/?type=post&id=68414&key=user_uploads/1162081/821f585b-f832-4df7-8b91-21ca677a0d14)\n\nDon’t see the test you’re looking for? Let know at [info@scanbase.com](mailto:info@scanbase.com).\n\n![uploaded image](/media/?type=post&id=68414&key=user_uploads/1162081/2809d76e-b3e0-405f-925c-82af759f4115)\n\n[Book a demo](https://www.scanbase.com/schedule-a-demo) and learn how Scanbase can enhance your diagnostic program.\\\n\\\n**We believe that everyone deserves access to the best healthcare technology has to offer.** Founded in 2022 and based in San Francisco, California, Scanbase is an API that allows medical companies to enable smartphone-based computer vision quickly so anyone anywhere can analyze their at-home test results with confidence.\\\n\\\nIf you are interested in learning more or joining our team, shoot us an email at [info@scanbase.com](mailto:info@scanbase.com) and we’ll get back to you right away.", "url": "https://www.ycombinator.com/launches/HnS-scanbase-api-converting-diagnostic-tests-to-results-next-steps-and-treatment", "votes": 109, "created_at": "2023-01-13T09:08:29.284Z" } ] }, { "id": 28859, "name": "MICSI", "slug": "micsi", "former_names": [ "MICSI (Microstructure Imaging, Inc)" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/29d35560d45b90c5227b12877556942576e43627.png", "website": "https://www.micsi.co/", "all_locations": "New York City, NY, USA", "long_description": "MICSI is introducing AI software that doubles resolution and halves scan time. This breakthrough enables imaging centers to significantly enhance their capacity and patient throughput, potentially saving countless lives and generating an additional $2 million of revenue per MRI scanner. Our initial offering serves as a stepping stone toward the company’s larger vision of transforming the MRI into a truly quantitative instrument that is capable of providing highly reproducible data for more accurate diagnoses and patient management. ", "one_liner": "Higher resolution MRI with faster scan times.", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1687381964, "tags": [ "Computer Vision", "Medical Devices", "Healthcare" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2023", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/micsi", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2023/micsi.json", "year_founded": 2018, "city": "New York City", "country": "US", "linkedin_url": "https://www.linkedin.com/company/microstructure-imaging-inc/", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/29d35560d45b90c5227b12877556942576e43627.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 1352304, "full_name": "Gregory Lemberskiy", "title": "Founder", "founder_bio": "Gregory Lemberskiy (CEO) co-founded MICSI with goal of bringing cutting edge image processing tools, that he encountered in the research setting into clinical practice. His PhD work (2019) focused on algorithm development for image enhancement and biophysical modeling of the MRI signal. His methods have been used to enable high-end quality on low field MRI systems through noise reduction (MICSI’s first product) and use MRI to characterize the physical properties of prostate glandular lumen.", "is_active": true, "linkedin_url": "https://linkedin.com/in/gregory-lemberskiy", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/83bae6427877568348313403492a3c5c90b7ff0c.jpg" }, { "user_id": 1352419, "full_name": "Benjamin Ades-Aron", "title": "Founder", "founder_bio": "I got my PhD in electrical engineering in 2022 from NYU, where I specialized in developing machine learning based computer vision algorithms for the visualization of MRI data. I specialize in developing software to process and route diffusion and functional MRI data, with a goal of improving image signal, reducing noise, and producing clinically viable diagnostic imaging biomarkers.", "is_active": true, "linkedin_url": "https://linkedin.com/in/benjamin-aron-b0313349", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/894ba3227d1a30f75b7086a428e64dbf24f4a090.jpg" } ], "jobs": [], "news": [], "launches": [ { "id": 96226, "title": "MICSI-PET: Anatomical Positron Emission Tomography", "tagline": "Making PET imaging fast, anatomical, and scalable for Alzheimer’s care.", "body": "TLDR; MICSI-PET makes PET imaging fast, anatomical, and scalable for Alzheimer’s care.\n\n![uploaded image](/media/?type=post&id=96226&key=user_uploads/1352304/a5488138-be4b-4093-86c1-1b2663488117)\n\n**Problem:** **PET is the bottleneck capping the entire Alzheimer’s market.**\n\n![uploaded image](/media/?type=post&id=96226&key=user_uploads/1352304/40ba7516-1b46-454a-9a26-98fb91fe3169)\n\nDisease modifying Alzheimer’s drugs like Leqembi and Kisunla are here, and they are projected to generate $5-8B/year by 2030. However, to get these drugs, patients need a positive amyloid PET scan.\n\nThis is an ambitious figure that is limited by the fact that there are only 2500 PET/CT scanners in the US, where the average age is 14 years old. PET scanners have a predictable 4-5% drop in sensitivity (or detected count rate) per year \\[Watanuki et al. Ann Nucl Med. 2010\\], suggesting a loss of half of the sensitivity since its initial install. Operationally, this sensitivity loss forces centers to lengthen acquisitions or increase dose just to preserve image quality, reducing throughput or margins right as amyloid PET demand is exploding. It’s also unrealistic to assume that the existing PET fleet is built for imaging Alzheimer’s at scale. PET systems are also heavily utilized for oncology, cardiology, infection, and presurgical planning, where 74% of all PET scans use FDG, a general purpose tracer for cellular metabolism. \n\n**Solution: Transform aging PET fleets into Anatomical PET with MICSI-PET.**\n\n![uploaded image](/media/?type=post&id=96226&key=user_uploads/1352304/be3b873c-3dd7-4326-8447-316161d179db)\n\nMICSI-PET is a turnkey upgrade that dramatically enhances PET image quality by using the MRI as an anatomical guide. This process does not require any additional imaging as all patients should have received an MRI prior to amyloid PET imaging. Operationally, this upgrade removes the primary barrier for scaling Alzheimer’s therapies by (1) enabling high-end PET imaging on low-end or aging PET scanners; (2) enabling shorter PET examinations leading to greater throughput; (3) minimizing ambiguity of positive/negative amyloid PET imaging by showing clearer boundaries between gray and white matter:\n\n![uploaded image](/media/?type=post&id=96226&key=user_uploads/1352304/90dd7722-405d-4a4f-967b-4ec6df183ff6)\n\n**Figure:** Coregistered conventional PET and MICSI-PET amyloid images across a range of amyloid burdens, highlighting differences in apparent cortical sparing: **left, amyloid-negative** with strong gray/white contrast; **right, amyloid-positive** with reduced gray/white contrast.\n\n**Addressing the Radiologist Workforce Crisis:** Scaling Alzheimer's care isn't just a hardware problem; it's a workforce problem. AD imaging is about to become a high-volume modality layered onto a nuclear medicine workforce where 54% of radiologists already report burnout.\n\nBeyond anatomical PET, MICSI-PET is designed to streamline diagnosis through automatic SUVR/Centiloid reporting with built-in QC.\n\n![uploaded image](/media/?type=post&id=96226&key=user_uploads/1352304/b48c9a16-d7b6-4fe9-bf74-509653e159dd)\n\nFast and anatomical PET is just the start. The same MR-guided upgrade would generalize across tracers, and eventually across doses, elevating the global standard of PET toward a new default: molecular imaging that’s both specific and anatomically precise. \n\nOur first product, MICSI-RMT, is already FDA-cleared and in the market. MICSI-PET is currently in clinical validation and we are preparing our FDA submission.\n\n**Ask:** We are expanding pre-FDA clearance pilot collaborations to validate MICSI-PET across sites and workflows, and we are closing a seed extension to support multi-center validation and early installs. If you lead a PET imaging program or invest in medical imaging and Alzheimer’s care, we would love to connect.  \n\n**Email Us:** \n\n[**Gregory.Lemberskiy@micsi.com**](mailto:Gregory.Lemberskiy@micsi.com)\n\n[**Benjamin.Adesaron@micsi.com**](mailto:Benjamin.Adesaron@micsi.com)", "url": "https://www.ycombinator.com/launches/P22-micsi-pet-anatomical-positron-emission-tomography", "votes": 16, "created_at": "2025-12-16T00:02:25.484Z" }, { "id": 73719, "title": "MICSI (Microstructure Imaging)", "tagline": "Higher resolution MRI acquired faster", "body": "TLDR; MICSI is introducing an innovative image processing algorithm to decrease MRI scan time, increase image resolution, and unlock new diagnostic capabilities using Microstructure Imaging.\n\n![](https://lh4.googleusercontent.com/166C-4hbfRCmiC20D9EbOVhdubPqEE3tuTb-ZvNh8bnOXts8Rf9ZfhssNQ8ptJsGYAFqtkSt6w9Cu-aRvnBDBoKesDzc1ou7ddUVUZqTZ0knq8MmlZsbLWYY4rpGoFqUmrbmjEeSjfMx7KMKRdEngWA)\n\n**Problem: MRI Centers are overbooked.**\n\nIf you've ever had an MRI, you've probably waited weeks for an available slot and then spent a long time in the scanner. These long scan times inconvenience patients, create hospital backlogs, and delay appointments. Delays like these can critically impact conditions that require prompt diagnosis and intervention, inflate healthcare costs, increase patient anxiety, and potentially compromise treatment strategies. Why the wait? An MRI of the whole brain can be acquired in [**seconds**](https://mriquestions.com/echo-planar-imaging.html)!\n\n**Compromise: Why is your MRI an hour long?**\n\nMost of the scan time is spent on preserving signal-to-noise ratio (SNR) to produce images of the highest quality. These standard SNR preserving methods include:\n\n* Line-by-line acquisitions: These are fax-machine-like acquisitions that read the image one line at a time, where the time spent on each line is equivalent to the time that could have been spent acquiring the whole image.\n* Averaging: To boost SNR, images may be reacquired and averaged together. However, SNR improves slowly as a square root of scan time (ie 4 images are required to double the SNR).\n\nAn additional compromise is related to the spatial resolution, since MRI is acquired in 3D with “voxels”, doubling the resolution in each dimension from (2x2x2 mm3 to 1x1x1 mm3) would require the SNR to increase by **8x**, which even after 50 years of innovation, seems near impossible.\n\n![](https://lh4.googleusercontent.com/y1p1DzihqAvnmKvtoSJAbVSBrInECVUP2GvzVc5TFmLNqwTQ1hevnLgcPX7iplxNhKchrjAAQq8L8WlPbLNVWX31jAN-VIg6dSJ7Nzv-lKMUTvy8xsUIlzfFOZLlgSoGL0ZAC1lk8xqtYL2V4Q1caJk)\n\n**The MRI exam is full of compromise.**\n\n* Long scan times means fewer patients can be scanned by a given radiology center.\n* Lower resolution means a compromise in anatomical accuracy, where pathologies that could have otherwise been detected at an earlier stage would need to progress further to be MR visible.\n\nWe believe that the ultimate compromise is that MRI is not being used to its fullest potential for microstructure imaging, where MRI could be used to [**image cellular properties non-invasively**](https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/abs/10.1002/nbm.3998).\n\n**Solution: Boosting SNR over the MRI exam using MICSI-RMT.**\n\nOur patented approach (pending FDA510k clearance in Q4-2023) uses a self-supervised AI method to learn the noise properties of the MRI exam and remove noise uniformly across all images of the dataset. Our algorithm, MICSI-RMT, can be described as a smart averaging approach, whereby many images of the MRI exam are combined while preserving their unique image properties and discarding the noise. This boost in SNR would be approximately, sqrt(M/P), where M is the number of images included in the dataset, whereas P describes how different the images are (physical properties: proton density, T1, T2, diffusion, etc + artifacts: motion, errors, etc).\n\nMICSI-RMT is the commercial implementation of the MP-PCA algorithm that was developed by our research group led by Drs. Dmitry S. Novikov and Els Fieremans of NYU Radiology’s Center for Biomedical Imaging.\n\nMP-PCA is the most popular denoising approach in the MRI community:\n\n* The [**original paper**](https://pubmed.ncbi.nlm.nih.gov/27523449/) introducing the approach has achieved over 1300 citations since November 2016.\n* Denoising of [**task-based FMRI**](https://pubs.rsna.org/doi/full/10.1148/radiol.2020200822) for presurgical planning of Neurosurgery\n* Enabling low field [**0\\.55T prostate diffusion**](https://pubmed.ncbi.nlm.nih.gov/37222526/) MRI\n\nWith MICSI-RMT, MRI centers will not only be able to provide higher quality imaging but also drastically reduce the scan time (up to [50%](https://pubs.rsna.org/doi/full/10.1148/radiol.2020200822)). This improved efficiency allows centers to scan more patients per day, enhancing their operational capacity and throughput. Financially, this increase in capacity translates into a significant boost in revenue for every MRI center. By doubling the number of patients scanned daily, we estimate an additional $2 million in annual revenue per MRI scanner. Furthermore, the improved image quality and resolution could lead to more accurate diagnoses, early disease detection, and reducing overall healthcare costs in the long run.\n\n**Who we are - Greg and Ben**\n\n![](https://lh6.googleusercontent.com/F5FGyVn85R_Oxvkgw_uEOhvkKUEg_2VemnSso8p1nBfc7vgYVd1q1Vnt2BgIJrm2CRenojq9RkwoxbuP0lebYfKIcs6anX6wQEPQj0T-yaTJGLBOvqqzsw4JL4ftzrHLozX-QX592SesWUotkt92ZCw)\n\nWe are scientists and engineers who have spent the last decade developing machine learning software to both improve the quality diagnostic utility of MRI. [**Gregory Lemberskiy, PhD**](https://www.linkedin.com/in/gregory-lemberskiy/) is an [**experimental physicist**](https://scholar.google.com/citations?user=_TvugCIAAAAJ&hl=en). He discovered how to use MRI to measure the diameter of the [**prostate glandular lumen**](https://www.frontiersin.org/articles/10.3389/fphy.2018.00091/full), which may obviate the need for tissue biopsy to detect prostate cancer progression. [**Benjamin Ades-Aron, PhD**](https://www.linkedin.com/in/benjamin-aron-b0313349/) is an [**electrical engineer**](https://scholar.google.com/citations?user=xNhHFuAAAAAJ&hl=en) who developed and deployed the [**DESIGNER**](https://pubmed.ncbi.nlm.nih.gov/30077743/) open-source image processing pipeline, which is the global gold standard of diffusion MRI image processing. He has also developed a number of novel neural network architectures to aid in the denoising of compressed sensing MRI data, to facilitate brain mapping for functional neurosurgery of Epilepsy and brain tumor.\n\nTogether, the MICSI team owns over a dozen approved patents and has a clear vision for the future of MRI. The goal of MICSI is to use our patented denoising and parameter estimation technologies to make MRI quantitative and reproducible for the first time, creating a new category in diagnostic healthcare and improving patient satisfaction and outcomes.\n\n**Our Ask**\n\n* Do you know anyone in private practice, hospitals, or in large academic centers who may be interested in our approach? We want to talk to them.\n* Questions, comments, feedback? We want to hear from you!\n\n**Email us:**\n\n[**Gregory.Lemberskiy@micsi.com**](mailto:Gregory.Lemberskiy@micsi.co)\n\n[**Benjamin.adesaron@micsi.com**](mailto:Benjamin.adesaron@micsi.co)", "url": "https://www.ycombinator.com/launches/JB1-micsi-microstructure-imaging", "votes": 23, "created_at": "2023-08-02T17:20:50.834Z" } ] }, { "id": 28891, "name": "Numen", "slug": "numen", "former_names": [ "Cleancard" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/801ff758c035f5849acfdcd35329ec161bd30cef.png", "website": "https://www.numen.com", "all_locations": "San Francisco, CA, USA", "long_description": "", "one_liner": "Engineering a future without cancer deaths.", "team_size": 18, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1691571179, "tags": [ "Machine Learning", "Biotech", "Healthcare", "Diagnostics", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Summer 2023", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/numen", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2023/numen.json", "year_founded": 2021, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/76116332", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/801ff758c035f5849acfdcd35329ec161bd30cef.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": { "name": "Ankit Gupta", "url": "https://www.ycombinator.com/people/ankit-gupta" }, "founders": [ { "user_id": 863380, "full_name": "Luca Springer", "title": "Founder", "founder_bio": "Luca is an expert in network science and computational game theory. He also has a strong policy background with a focus on healthcare systems. Luca previously worked at Stockdale Street, where he gathered years of experience analyzing, investing in, and helping grow healthcare, consumer, and technology companies. He holds an MSc in Computer Science and an MSc in Global Governance from the University of Oxford where he studied as a Rhodes Scholar. Luca is a Schmidt Futures ISF Fellow.", "is_active": true, "linkedin_url": "https://linkedin.com/in/luca-springer-b3801b8a", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/d3953e4f6336e741bb8cfd4657d9d3b3622852aa.jpg" }, { "user_id": 863406, "full_name": "Thomas Carroll", "title": "Founder", "founder_bio": "Clinical cancer researcher with a specialty in bioinformatics, biomarkers, and methods development. Passionate about building better diagnostics and putting a dent in cancer mortality.", "is_active": true, "linkedin_url": "https://linkedin.com/in/thomas-carroll-62a60367", "x_url": "https://twitter.com/_tom_dot_com", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/6730b7b4c46770d90b1cc88259531421c45248dc.jpg" } ], "jobs": [ { "id": 99608, "title": "Visual Designer", "url": "https://www.ycombinator.com/companies/numen/jobs/AaAkTx0-visual-designer", "location": "San Francisco, CA, US", "type": "Full-time", "role": "Design", "role_type": "UI / UX", "salary_range": "$90K - $140K", "equity_range": "0.05% - 0.10%", "experience": "1+ years", "visa": "US citizen/visa only", "skills": [] } ], "news": [], "launches": [ { "id": 73949, "title": "💧🧬Cleancard - Making cancer screening as easy as a pregnancy test", "tagline": "Combining SynBio and AI to make rapid and reliable at-home cancer testing possible", "body": "**Tl;dr:** We’re Cleancard, a pair of Rhodes Scholars on a mission to reinvent cancer diagnostics. We combine synthetic biology + AI to create powerful at-home cancer tests, with results from urine in just 30 minutes. **Check out our **[**website**](https://www.cleancard.bio/)** for more!**\n\nHey everyone - we’re Tom and Luca, the co-founders behind Cleancard!\n\n![uploaded image](/media/?type=post&id=73949&key=user_uploads/863380/9ea23e71-c6d5-4715-8236-7ed89e1d6a90)\n\n👨🏻 [Tom](https://www.linkedin.com/in/thomas-carroll-62a60367/): Clinical cancer researcher, expert in bioinformatics and methods development. No stranger to designing [better biomarker tests](https://www.cell.com/cancer-cell/fulltext/S1535-6108(23)00216-7). 👨🏻‍🦰 [Luca](https://www.linkedin.com/in/luca-springer-b3801b8a/): Computer scientist with a strong healthcare policy background. Years of experience growing healthtech and consumer businesses.\n\n### **Early cancer detection saves lives 🕑**\n\nMore than 18M Americans have cancer today. Unfortunately, this is a growth market (26M projected by 2040). 1 in 3 have a close family member with a history of cancer, and thus have a higher risk for cancer themselves (2x). We know these realities all too well from our personal lives, dealing with hereditary cancer syndromes and family histories of cancer.\n\nCancer will come for many of us. To give ourselves drastically better odds of surviving this disease, we need to diagnose it before it reaches an advanced stage.\n\n![uploaded image](/media/?type=post&id=73949&key=user_uploads/863380/10066d6b-22e6-4e98-a5cf-4fc34047d766)\n\n### **Problem: Cancer screening is failing us 🤬**\n\n* Cancer symptoms are often unnoticeable until the cancer is too advanced to cure\n* Current lab-based screening tests are **time-consuming** and **costly** - they fail to get people to screen before they are symptomatic (even for PSA, only [1 in 3 participate](https://jamanetwork.com/journals/jamaoncology/fullarticle/2797845))\n* At-home rapid tests would increase rates of asymptomatic screening but **just don’t perform well enough** to be trusted for cancer diagnostics\n* Current options are **not sufficient** to give people their best chance at surviving cancer\n\n### **Solution: Cleancard’s rapid testing platform 😍**\n\nWe’ve built a new rapid-test method enabling highly sensitive biomarker-guided diagnostics from the urine in just 30 minutes. Key advantages of our proprietary technology:\n\n* **10x quicker/cheaper** than lab-based tests\n* **10x more sensitive** than lateral flow\n* **No expensive machinery** or **complicated sample manipulation**.\n\nSee how we stack up:\n\n![uploaded image](/media/?type=post&id=73949&key=user_uploads/863380/ed2218af-7627-4f5b-9d17-7adec46c6632)\n\nCleancard technology combines synthetic biology, machine learning, and computer vision into a multiplexable, machine-readable format which allows us to detect multiple cancer biomarkers from a single sample.\n\nOur first rapid at-home screens will identify prostate, bladder, and ovarian cancers. Our method is highly agile - we’ve successfully targeted 10 new cancer biomarkers during this YC batch alone, with more to come soon. \n\nCleancard’s platform is the one-stop shop for reliable detection and tracking of multiple cancer biomarkers in the comfort of your own home.\n\n### **Our asks 🙏**\n\n* **Share this post!** Please help us spread the word with your networks.\n* **Join our team!** We are always looking for highly motivated scientists and engineers to join us in our mission to reinvent cancer diagnostics. If that’s you or someone you know, please get in touch ([contact@cleancard.bio](mailto:contact@cleancard.bio)).", "url": "https://www.ycombinator.com/launches/JEj-cleancard-making-cancer-screening-as-easy-as-a-pregnancy-test", "votes": 46, "created_at": "2023-08-09T15:57:45.669Z" } ] }, { "id": 29484, "name": "Haplotype Labs", "slug": "haplotype-labs", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/d7043e2a3ba867786a1c7649c0cda610207599ea.png", "website": "https://www.haplotypelabs.com/", "all_locations": "San Francisco, CA, USA; Remote", "long_description": "We're building the HaploHub: a SaaS platform for genetic testing labs, concierge medical practices, and payer/providers to: \r\n * predict disease risk for their patients based on proprietary or publicly available genetic models\r\n * securely host, manage, and interrogate the genetic data of their population\r\n * generate reports and run the most common inference algorithms (phasing, imputation, ibd, etc.) without writing code \r\n\r\n", "one_liner": "Personalized prevention using genetics and AI", "team_size": 1, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1707335059, "tags": [], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Winter 2024", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Fully Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/haplotype-labs", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2024/haplotype-labs.json", "year_founded": 2024, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/haplotype-labs/", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/d7043e2a3ba867786a1c7649c0cda610207599ea.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 1647013, "full_name": "Mike Polcari", "title": "Founder/CEO", "founder_bio": "Mike is the founder of Haplotype Labs.\nPreviously, Mike served as the VP & Chief Architect at 23andMe. Mike's tenure at 23andMe spanned a 15+ year category-defining journey from Series A through IPO.\nPrior to 23andMe, Mike was an early engineer at Salesforce.com and developed technology at Merrill Lynch.\nMike holds a BS in CS from Cornell, a MS in Biomedical Informatics from Stanford, and multiple patents related to cloud computing, security, genetics, and machine learning.", "is_active": true, "linkedin_url": "https://linkedin.com/in/polcari", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/0a5fe507f8ed320d33aa54b4ed1815adca6b60ff.jpg" } ], "jobs": [ { "id": 66442, "title": "Founding Member(s) of Technical Staff", "url": "https://www.ycombinator.com/companies/haplotype-labs/jobs/EfF0ixF-founding-member-s-of-technical-staff", "location": "Berkeley, CA, US / Remote (US)", "type": "Full-time", "role": "Engineering", "role_type": "Full stack", "salary_range": "$60K - $240K", "equity_range": "", "experience": "6+ years", "visa": "US citizen/visa only", "skills": [ "Amazon Web Services (AWS)", "Google Cloud", "Python", "Docker", "Bioinformatics", "Biostatistics", "Genomics" ] } ], "news": [], "launches": [ { "id": 79664, "title": "Haplotype Labs - Personalized prevention using genetics and AI", "tagline": "Our product, the HaploHub, makes the world's best genetic risk models available to precision prevention programs, clinical trials, and genetic testing labs using any laboratory, microarray or next generation sequencing technology.", "body": "Hi! I’m [Mike](https://linkedin.com/in/polcari), founder of [Haplotype Labs](https://www.haplotypelabs.com). At Haplotype Labs, we believe that more precise prevention and screening will lead to longer healthspan and lower healthcare costs. \n\n![uploaded image](/media/?type=post&id=79664&key=user_uploads/1647013/730b958e-b667-4136-968b-5543aa5b9090)\n\nWe're building the HaploHub: a software platform that helps genetic testing labs, clinical trials, and prevention-focused medical practices to deploy **AI models that use genetics to predict, detect, and prevent disease**.\n\nI joined 23andMe after Series A and helped take it public after over 15 years as VP / Chief Architect. The technology that my team and I developed at 23andMe has delivered more genetic risk reports to more patients than any other in the world, but the translation to patient outcomes remains unsolved. At Haplotype Labs, we are working to close that gap and accelerate the translation of polygenic risk scores into improved healthspan for patients. We’re building the tech I wish I’d had at 23andMe and making it broadly available to the clinic.\n\n**_Precision_ Preventative Care**\n\nPreventative care programs currently stratify patients into risk categories for various conditions based on imperfect but still useful risk factors like demographics and family history. Patient stratification allows a care provider to optimize the financial expense and negative side effects of any given prevention program. For example, people with a family history of colon cancer are typically screened more frequently.\n\nDriven by falling prices of sequencing and improved model power, preventative care is on the cusp of broadly adopting genetic risk models as a means to further personalize these prevention programs and extend healthspan. These models can also play a role in the discovery of new medicines, and can accelerate clinical trials.\n\nPublished methods are improving rapidly and new models are published consistently. However, it is difficult to correctly and reliably compare the performance of these models or deploy them at scale.\n\n**Advanced technology made simple**\n\nWe're building the HaploHub: an easy-to-use SaaS platform for genetic testing labs, concierge medical practices, clinical trials, consumer brands, and payers/providers to:\n\n* predict disease risk for their patients based on proprietary or 4000+ publicly available genetic models using any genome-wide germ-line or methylation assay\n* securely host, manage, and interrogate the genetic data of their population\n* run the most common inference algorithms (phasing, imputation, ibd, etc.) without writing code\n* transition to low-pass sequencing and save 50-90% on sequencing costs\n\n**Get in touch!**\n\nWe’re eager to get this technology out into the world! We would love to speak with concierge practitioners, clinical trial investigators, or anyone interested in using genetics to extend health span. If that sounds like you, please reach out!\n\n[yclaunch@haplotypelabs.com](mailto:yclaunch@haplotypelabs.com)", "url": "https://www.ycombinator.com/launches/Kiu-haplotype-labs-personalized-prevention-using-genetics-and-ai", "votes": 11, "created_at": "2024-03-25T15:28:50.228Z" } ] }, { "id": 29694, "name": "AminoAnalytica", "slug": "aminoanalytica", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/f7d5463656052d09bd1bc697531992af867d844c.png", "website": "https://www.aminoanalytica.com", "all_locations": "London, England, United Kingdom", "long_description": "We design point-of-care diagnostics for emerging biological threats - in days, not 12+ months.", "one_liner": "The AI scientist for always-on biodefense", "team_size": 3, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1715962434, "tags": [ "Nanosensors", "Synthetic Biology", "Biotech", "Diagnostics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2024", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United Kingdom", "Europe", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/aminoanalytica", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2024/aminoanalytica.json", "year_founded": 2024, "city": "London", "country": "GB", "linkedin_url": "https://www.linkedin.com/company/aminoanalytica/", "x_url": "https://x.com/aminoanalytica", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/f7d5463656052d09bd1bc697531992af867d844c.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 1754946, "full_name": "Abhi Rajendran", "title": "Founder/CEO", "founder_bio": "Ex-Mercedes Formula 1 engineer and computational biologist working to fight emerging biological threats", "is_active": true, "linkedin_url": "https://linkedin.com/in/abhirajen", "x_url": "https://x.com/amino_abhi", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/35c9daa80919f9ffbb985a3ae786e3c39a8cc183.jpg" }, { "user_id": 1754481, "full_name": "Adam Wu", "title": "Founder/CTO", "founder_bio": "Building the smartest protein engineer in the world.\n\nShameless plug: check out 'adwuu' on spotify for a good time", "is_active": true, "linkedin_url": "https://linkedin.com/in/akhwu", "x_url": "https://x.com/adaminoacid", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/6da79f1592a746e918638e3b0d0ef923773e7594.jpg" } ], "jobs": [], "news": [], "launches": [ { "id": 92017, "title": "Amina: The Agentic Protein Engineer", "tagline": "Design, simulate, and test your proteins 100x faster with our no-code platform for protein engineering!", "body": "**👋 Hey YC! We're Abhi and Adam from AminoAnalytica.**\n\n**Amina is the first AI agent for end-to-end protein engineering** – instead of wrestling with hundreds of fragmented tools, scientists can now design protein therapeutics through simple conversation.\n\n## **🎬 Trailer**\n\nhttps://www.youtube.com/watch?v=n8Pd9BJcbQA\n\n## **🧬 The Problem with Programmable Biology**\n\nThe 2024 Nobel Prize for Chemistry went to AlphaFold - proving we can predict and design proteins like software. These biological machines could solve climate change, cure diseases, and manufacture anything we need.\n\nBut here's the reality: **hundreds of new computational biology tools launch every week.** Even expert researchers stick to the same old methods they know, missing breakthrough tools that could accelerate their work by months or years.\n\n**Meet Dave, your friendly neighborhood protein engineer** 👨‍🔬\n\nDave is designing a cancer therapeutic, but his current workflow is broken:\n\n* **Inaccessible tools** → most have no UI, require specific hardware, must be built from source\n* **Fragmented ecosystem** → tools don't work together, requiring pages of glue code\n* **Constant obsolescence** → by the time he masters one tool, three better ones have launched\n\nThe result? **Scientists spend more time debugging code than designing life-saving therapeutics.**\n\n## **🚀 Our Solution**\n\n**What if you could just describe what you want in plain English?**\n\nInstead of wrestling with complex pipelines and staying up-to-date with every new tool, you simply tell Amina what protein you need and why.\n\n**Dave before Amina:**\n\n![uploaded image](/media/?type=post&id=92017&key=user_uploads/1754946/ad201bdd-6ed8-4b33-bb1f-fd8ca58f5262)\n\n**Dave with Amina:**\n\n![uploaded image](/media/?type=post&id=92017&key=user_uploads/1754946/3657d135-74af-4ed9-b261-394f14fe42a5)\n\n## **🔬 What Makes Amina Different**\n\nThis isn't just model hosting. Amina is trained on both scientific literature and our proprietary experience from engineering thousands of proteins for customers - it knows which tools to use when, how to chain them together, and how to interpret results. It's like having our entire computational team's expertise distilled into a single agent.\n\nWith our no-code interface, 50+ specialized tools work together seamlessly. Amina catches potential issues, suggests optimizations, and explains results in plain English.\n\n## **🎯 Our Vision**\n\n**Our ultimate goal is for Amina to design proteins autonomously** - think JARVIS, but dedicated to discovering breakthrough therapeutics. For now, it's like having an extra bioinformatician on your team that needs less care and attention than your cell cultures.\n\n## **🙏 Our Ask**\n\n**If you work in biotech, pharma, or have an interest in protein engineering** - we'd love your feedback on Amina.\n\n**Try it for free at [aminoanalytica.com](http://aminoanalytica.com)** - no setup required, start designing in 60 seconds.\n\nNeed extra credits? Just message us at [support@aminoanalytica.com](mailto:support@aminoanalytica.com)", "url": "https://www.ycombinator.com/launches/Nw9-amina-the-agentic-protein-engineer", "votes": 15, "created_at": "2025-07-09T18:31:25.117Z" }, { "id": 82706, "title": "🧬 AminoAnalytica – Next generation proteins engineered with *protein* language models", "tagline": "We’re creating the next generation of peptides and enzymes using our proprietary pipeline, powered by protein language models.", "body": "Hey everyone – it’s [Abhi Rajendran](https://www.linkedin.com/in/abhirajen/), [Adam Wu](https://www.linkedin.com/in/akhwu/) and [Matteo Peluso](https://www.linkedin.com/in/matteo-peluso-872b85199/)\n\n**Tl;dr**: just look at the pictures ;)\n\n# **💞 The A(mino) Team**\n\n![uploaded image](/media/?type=post&id=82706&key=user_uploads/1754946/96f298df-f236-4401-91d5-2ce61024e644)\n\n👨🏾 **Abhi Rajendran** – From Imperial College London to the Mercedes F1 Team, Abhi builds AI tools in data-intensive environments. AminoAnalytica was inspired by his computational bio master’s project and was the top AI x Robotics venture from Imperial in 2024.\n\n👦🏻 **Adam Wu** – With experience in academic and industry wet labs, Adam is now building his own. He has a background in materials science, tissue engineering and biosensing as a Thermo Fisher Scholar from Imperial.\n\n👱🏼‍♂️ **Matteo Peluso** – Bioinformatics PhD from the University of Zurich. His skills in biology, machine learning, and software development tie up everything seamlessly.\n\n👨🏻‍🦱 **Dr. Stefano Angioletti-Uberti** – Senior lecturer at Imperial, specializing in modeling biological and soft matter systems. He ensures models are based on the latest scientific principles.\n\n# **❌ Problem: better proteins are needed to accelerate global innovation**\n\n* Industrial and pharma companies prefer to use enzymes and peptides over harsh chemicals as they are more specific and sustainable.\n* However, natural proteins often lack stability, efficiency, or specificity for their desired applications leading to poor performance\n* Improving these proteins has been a costly and inefficient 'trial-and-error' process, where biotech companies randomly mutate existing proteins, test them, and repeat until success.\n\n![uploaded image](/media/?type=post&id=82706&key=user_uploads/1754946/afb4dbcf-6cc7-43e1-915e-609278e798fa)\n\n# **✅ Solution: AminoAnalytica’s protein adaptation platform, powered by PLMs**\n\n* Like how ChatGPT understands human language, our **\"protein language models\" (PLMs)** understand biology and can optimize proteins for industrial and therapeutic use.\n* This allows us to perform in-silico protein property prediction, eliminating the need for thousands of lab tests.\n* We’re transforming the traditional ‘trial-and-error’ method into an ultra-high throughput and rational process.\n\n![uploaded image](/media/?type=post&id=82706&key=user_uploads/1754946/65fb8e1a-d749-4245-adca-a0abc1ad8529)\n\n# **🤝 Any industry working with proteins can benefit from our tech**\n\nCurrently, we’re working on:\n\n* **Aquaculture feed** → enzymes for maximizing fish feed nutritional efficiency\n* **Pharmaceuticals** → peptide drugs with improved stability and specificity\n* **Climate tech** → enzymes for eco-friendly carbon capture\n* **Consumer goods** → safer enzymes for everyday products\n\n![uploaded image](/media/?type=post&id=82706&key=user_uploads/1754946/30bf87a9-4ee8-49e6-a0ee-7f8dd85bf008)\n\n# **🐡 Get in touch with us!**\n\n* Upvote/share this post with your network and help spread the word!\n* If you (or anyone in your network) are as excited as we are about next generation industrial proteins and would like to learn more about what we’re doing, email us here - [founders@aminoanalytica.app](mailto:founders@aminoanalytica.app)\n* We’re also looking to expand **our advisory board** in the areas of aquaculture, fish testing, and feed manufacturing!\n\n![uploaded image](/media/?type=post&id=82706&key=user_uploads/1754946/908a3520-d234-4338-ad05-154aa3515672)\n\n", "url": "https://www.ycombinator.com/launches/LVy-aminoanalytica-next-generation-proteins-engineered-with-protein-language-models", "votes": 138, "created_at": "2024-08-04T00:01:55.931Z" } ] }, { "id": 31434, "name": "Adialante", "slug": "adialante", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/783d9149e0d4fcedf1d788091598886930e15376.png", "website": "http://www.adialante.com", "all_locations": "San Francisco, CA, USA", "long_description": "We know how to improve cancer outcomes by 8x-10x: you catch it early. \r\n\r\nMRI is the most robust and powerful cancer-detection tool in the world, yet systems cost millions to purchase, take months to install, and require high levels of technical skill to operate. We've redesigned MRI from the ground up with new physics, algorithms, and hardware, all to bring cancer screening to the entire world. \r\n\r\nOur mobile MRI is an imaging clinic on wheels. No equipment to buy, no infrastructure needed. For a flat per-scan fee, any medical site can offer MRI cancer screening. Starting with prostate cancer. Then everything else.", "one_liner": "Cancer screening without barriers", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1773702631, "tags": [], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Spring 2026", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/adialante", "api": "https://devasheeshg.github.io/yc-api/batches/spring-2026/adialante.json", "year_founded": 2023, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/adialante/", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/783d9149e0d4fcedf1d788091598886930e15376.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": { "name": "Nicolas Dessaigne", "url": "https://www.ycombinator.com/people/nicolas-dessaigne" }, "founders": [ { "user_id": 1230366, "full_name": "Efrain Torres", "title": "Founder/CEO", "founder_bio": "CEO, making MRI a mass market cancer screening tool. ", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/dr-efra%C3%ADn-torres-85293512a/", "x_url": "https://x.com/ET_adialante", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/452cd32ba0ca720ba8d2cfc14183bb72b94ac899.jpg" }, { "user_id": 1298954, "full_name": "Parker Jenkins", "title": "Founder/COO", "founder_bio": "COO at Adialante. Making cancer screening affordable. ", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/parker-jenkins-486893130/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/d03c5ef3dc4acc819f5d3dc4916e815946a04780.jpg" } ], "jobs": [ { "id": 98651, "title": "Electrical Engineer", "url": "https://www.ycombinator.com/companies/adialante/jobs/UMcHMIR-electrical-engineer", "location": "Menlo Park, CA, US", "type": "Full-time", "role": "Engineering", "role_type": "Electrical", "salary_range": "$90K - $130K", "equity_range": "0.25% - 0.85%", "experience": "Any (new grads ok)", "visa": "Will sponsor", "skills": [ "CAD Design", "Prototyping", "PCB design" ] }, { "id": 104459, "title": "Senior Quality Engineer", "url": "https://www.ycombinator.com/companies/adialante/jobs/XczOeQ5-senior-quality-engineer", "location": "Menlo Park, CA, US", "type": "Full-time", "role": "Operations", "role_type": null, "salary_range": "$130 - $165", "equity_range": "0.25% - 0.85%", "experience": "3+ years", "visa": "US citizen/visa only", "skills": [] }, { "id": 104460, "title": "MRI Tech ", "url": "https://www.ycombinator.com/companies/adialante/jobs/OyWyAGn-mri-tech", "location": "Minneapolis, MN, US", "type": "Contract", "role": "Operations", "role_type": null, "salary_range": "$9K - $9.2K / monthly", "equity_range": "", "experience": "1+ years", "visa": "US citizen/visa only", "skills": [] } ], "news": [], "launches": [ { "id": 101289, "title": "Adialante: We're going to screen the world for cancer!", "tagline": "Our second patent just issued, a new way to make MRI.", "body": "**TLDR**: Adialante builds compact and mobile whole-body MRIs. We already have $12.75M in LOIs, $30k in deposits, and our first system will be scanning by demo day.\n\n---\n\n##### **About Us:**\n\n\\\n\\\n\"Disruptive Innovation describes a process by which a product or service takes root in simple applications at the bottom of the market — typically by being less expensive and more accessible — and then relentlessly moves upmarket, eventually displacing established competitors.\" — Christensen Institute\n\nWe’re [@Efrain Torres](https://bookface.ycombinator.com/user/1230366) and [@Parker Jenkins](https://bookface.ycombinator.com/user/1298954), the co-founders of [@Adialante](https://bookface.ycombinator.com/company/31434). We met on the first floor of our engineering dorm. And when we learned what disruptive innovation was, it captured us immediately. But what to disrupt? Trained as biomedical engineers, we both learned about MRI and were in awe of the clinical value. It can diagnose cancers, strokes, dementia, and more. Yet everyone said the same thing: MRI is not accessible.\n\nSo we knew what we had to do: disrupt the industry.\n\nOver the past six years, we've invented new ways to do MRI, won millions in competitive grants, published research, secured patents (#12,625,209, #12,372,595, more to come), and built a team. And, now, we’re well on our way to disrupting the industry.\n\n##### **Problem:**\n\nWe know how to 10x cancer outcomes: **you catch it early**. MRI is the most powerful cancer-detection tool in the world, yet systems cost millions to purchase, take months to install, and require high levels of technical skill. The result? We only use MRI when it's too late.\n\n##### **Our solution:**\n\nWe've redesigned MRI from the ground up with new physics, algorithms, and hardware, all to bring cancer screening to all of us. Our MRIs:\n\n* use 50% less hardware\n* are 40% shorter and 80% lighter\n* are whisper-quiet and much less claustrophobic\n* and require no specialized infrastructure\n\nAll while maintaining the diagnostic quality patients need.\n\n![uploaded image](/media/?type=post&id=101289&key=user_uploads/1230366/e7c9bf11-8868-457b-aced-78bd369559f5)\n\nBut like Waymo, we won't sell our hardware — we'll own and operate it. We'll bring our MRIs to clinics in mobile trailers, handle its operations, and continuously improve our AI software after every scan. We're an imaging clinic on wheels. So instead of a clinic waiting months and paying millions, clinics will wait hours and pay hundreds.\n\n![uploaded image](/media/?type=post&id=101289&key=user_uploads/1230366/31ce218b-56df-4fc3-9450-5af5eea83895)\n\n---\n\nWe're starting with prostate cancer. **Over 1M men every year require an MRI before a prostate biopsy, but virtually none of the urology clinics that treat them can offer one.**\n\nAfter our per-scan fee, a clinic will collect the insurance reimbursement and make a profit. It's a win-win-win: we get the recurring revenue, they get a new revenue stream, and patients get the best imaging technology in the world. From there, the same piece of hardware expands to renal, breast, and brain scanning **until annual screening for high-risk cancers is the norm, not the exception.**\n\n**Traction:**\n\n* 6 clinics signed up\n* $12.75M in LOIs for scanner utilization\n* $30k deposited from a top ten urology clinic to reserve their spot in line\n* MRI assembled\n\n ![uploaded image](/media/?type=post&id=101289&key=user_uploads/1230366/1fa5afed-cb5b-4f8d-a3f0-46a430043c0e)\n\n\n##### **Asks:**\n\nIntros to Urology clinics\n\n##### **Open Invitation:**\n\nWant to see our scanner? Shoot us a message! We’ll show you our system in person!", "url": "https://www.ycombinator.com/launches/QLh-adialante-we-re-going-to-screen-the-world-for-cancer", "votes": 31, "created_at": "2026-05-13T18:24:48.396Z" } ] } ]